1. 减毒沙门氏菌携带GRIM-19及Survivin-特异shRNA共表达质粒对前列腺癌的治疗作用 2. 有机硒抑制激素非依赖性前列腺癌的发生
|
摘要
Survivin是前列腺癌高表达基因,GRIM-19基因(gene associated with retinoid-IFN-induced mortality 19)是一种由IFN-β联合维甲酸诱导表达的细胞死亡调节因子,其过度表达会导致细胞凋亡。应用RNAi技术沉默Survivin可达到抑制前列腺癌生长的作用,为提高其抗肿瘤效应,联合GRIM-19与之建立共表达载体以加强促细胞凋亡效应;体外实验已证明甲基硒酸(MSA)具有抗雄激素依赖性前列腺癌的作用。
目的: (1)通过体内外实验探讨pGRIM-19-si-Survivin共表达质粒抗前列腺癌作用与机制;探讨减毒沙门氏菌作为该共表达质粒运载体进行体内实验的可行性。(2)在成功建立去势后复发型前列腺癌模型的基础上,探讨甲基硒代半胱氨酸(MSC)抑制激素非依赖性前列腺癌的发生并探讨相关机制。
方法:(1)应用脂质体法将pGRIM-19-si-Survivin共表达质粒及对照质粒转染至人前列腺癌细胞DU145内,通过MTT法检测细胞增殖抑制情况,流式细胞术等观察细胞周期与凋亡,以RT-PCR、Western blot法检测目的基因与相关基因和蛋白的表达;复制裸鼠前列腺癌皮下移植瘤模型,腹腔注射携带pGRIM-19-si-Survivin共表达质粒等的减毒沙门氏菌,进行抗肿瘤作用与机制的研究。(2)复制裸鼠前列腺癌去势后复发模型,观察MSC对前列腺癌雄激素依赖性的影响。.
结果:(1)通过体内外实验证明pGRIM-19-si-Survivin共表达质粒的抗前列腺癌作用优于单基因治疗组,显示出明显的协同效应:①增殖抑制实验结果显示,共表达质粒显著地抑制DU145细胞的增殖活性;②流式细胞术和Annexin V-FITC等检测分析发现:共表达质粒的促凋亡作用最为显著;③DU145细胞的免疫荧光染色显示Survivin的表达聚集在细胞核及其周围的胞浆中;④共表达质粒组Stat3、c-Myc、cyclinD1、BcL-xL和VEGF基因和蛋白表达明显抑制,而caspase3的基因与蛋白表达显著上调。体内实验证明,携带pGRIM-19-si-Survivin共表达质粒的减毒沙门氏菌治疗组的抗肿瘤作用最明显,主要是通过促凋亡作用实现的;(2)MSA体外可抑制人激素依赖性前列腺癌LNCaP细胞的增殖并降低雄激素受体表达;MSC可抑制去势诱导的激素非依赖性前列腺癌的发生。
结论:减毒沙门氏菌携带pGRIM-19-si-Survivin共表达质粒,在抗前列腺癌作用中显示明显的协同作用;MSC可抑制去势诱导的激素非依赖性前列腺癌的发生。本研究所采用的技术路线及实验结果在国内外均未见报道。
1 Attenuated Salmonella typhi carrying theplasmid-co-expressed GRIM-19 and Survivin-specific shRNA for prostate cancer therapy
Prostate cancer is a common malignant tumor which is harmful to male of middle and old age. There is no ideal treatment except early prostate cancer could be effectively treated by radical operation. A high degree of malignant prostate cancer tends to micrometastasis earlier. So it is very significant to search the candidate which is no toxic but effective. RNA interference (RNA interference, RNAi) technology was a great discovery and had been used for the treatment of many diseases at the end of the 20th century in academic medicine. The main material of RNAi is the long double strand RNA (dsRNA), when it goes into the cell it is cleavaged into short dsRNAs with 21-23 nucleotides which are called siRNA (small interfering RNA also called short double-stranded RNA), siRNA is a sequence-specific post-transcriptional gene silencing mechanism, which is triggered by double-stranded RNA (dsRNA) and causes degradation of mRNA homologous in sequence to the dsRNA. This new approach has been successfully adopted to inhibit tumorigenicity. RNAi technology is currently being evaluated not only as an extremely powerful instrument for functional genomic analyses, but also as a potentially useful method to develop specific dsRNA based gene-silencing therapeutics.
The target gene-specific siRNA preparation method:①Chemical synthesis: this type of siRNA goes into the cell directly and plays a key role but with high price, easily degradated and short half-life;②Preparation of siRNA recombinant plasmid: Endogenous delivery is possible by inserting DNA templates for siRNAs into RNA polymeraseⅢ(polⅢ) transcription units, which are based on the sequences of the natural transcription units of the small nuclear RNA U6 or the human RNase P RNA H1. the approach is available for expressing siRNAs with stability. With the development of the RNAi technology and deeper understanding of this field, a promising new modality of treatment appeared, which can be used in combination with the existing therapies for prostate cancer therapy.
We based on the fact that the siRNA-Survivin had significant role in inhibiting the growth of prostate cancer. In order to improve its anti tumor effect we took the cell death regulator GRIM-19 (gene associated with retinoid-IFN-induced mortality19, to construct pGRIM-19-siRNA -Survivin co-expression plasmid and explore its synergistic anti-prostate cancer effect.
Recombinant plasmid carrier research: RNAi technology drug is highly efficient, very small amounts of RNAi inducer could make specific target genes silence, reverse the malignant phenotype of tumor cells and induce apoptosis of tumor cells. However, the recombinant plasmid expressing siRNA can not penetrate cell membrane. The delivery of RNAi effector to target cells is one of the key factors determining therapeutic efficacy, because gene silencing is limited to cells reached by RNAi effectors. The biggest challenge is how to solve the carrier. In recent years, studies have demonstrated that attenuated Salmonella typhi has tropic-tumor activity. The preliminary research confirmed that the attenuated Salmonella typhi had gathered in solid tumor. Compared with normal tissue, the reproductive advantage was more than 1,000 times. In addition, it not only grew in severe hypoxia of solid tumors but also in the micrometastasis tumor, and had the effect of tumor lysis. In particular, attenuated Salmonella typhi (Ty21a) as an oral vaccine carrier have been used for 25-year in clinic. Therefore, this article selected attenuated Salmonella typhi as carrier for pGRIM-19-siRNA-Survivin recombinant plasmid for the delivery of anti-prostate cancer research.
1.1 Objective:
Attenuated Salmonella typhi carrying pGRIM-19-siRNA-Survivin co-expression plasmid as delivery vector for anti-prostate cancer research was applied. The aim is to explore the pGRIM-19-siRNA-Survivin expression plasmid whether or not had synergic effect in the role of anti-prostate cancer and confirm the feasibility of Attenuated Salmonella typhi as delivery for prostate cancer xenografts therapy.
1.2 Methods:
1.2.1 pGRIM-19-siRNA-Survivin expression vector constructed successfully: As psi-Survivin plasmid as a template, PCR was applied for amplification of U6 promoter and the psi-Survivin sequence, then the PCR products were cloned into the pGRIM-19 eukaryotic expression vector to construct the co-expression pGRIM-19 -siRNA-Survivin plasmid which at the same time expresses si-Survivin and GRIM-19 gene
1.2.2 Studies In vitro:
Human androgen-independent DU145 prostate cancer cell lines were used for the project, recombinant plasmids were transfected into cells with lipofection. Cell proliferation was detected by MTT at different time; cell cycle and apoptosis were detected through flow cytometry (FCM), Annexin V-FITC kit, acridine orange staining and Tunel method. Survivin protein distribution with immunofluorescent staining ; the target gene and protein (Survivin, GRIM-19) and associated genes and protins (Stat3, c-Myc, CyclinD1, BcL-xL, caspase3 and VEGF) expressions by RT– PCR and Western blot
1.2.3 Studies in vivo:
In order to observe the anti-prostate cancer effect of the recombinant plasmids, we constructed nude prostate cancer xenografts hypodermically and injected Attenuated Salmonella typhi carrying different plasmids into peritoneal cavity to the tumor. We measured tumor volumes, compared tumor growth rates and tumor weights between groups at the same time. RT-PCR, Western blot and immunohistochemical staining were used to detect the target genes and proteins and associated genes and proteins (Stat3, c-Myc, cyclinD1, BcL-xL, caspase3 and VEGF); HE and TUNEL staining of tumor tissue for were used to detect the changes in morphology and apoptosis. Through the assays we evaluated the anti-prostate cancer effects and revealed the related mechanisms of the co-expression plasmid.
1.3 Results:
1.3.1 RT-PCR, immunohistochemistry and Western blot results showed that: gene and protein expressions of Survivin in prostate cancer and DU145 cells were significantly higher than that of normal prostate tissue, while the expressions of GRIM-19 significantly lower than normal prostate tissue.
1.3.2 We successfully constructed the co-expression pGRIM-19-siRNA-Survivin plasmid identified by restriction enzyme digestion and sequencing which has two promoters and expresses si-RNA-Survivin and GRIM-19 at the same time.
1.3.3 Results In vitro: the Survivin expression was dowenregulated in gene and protein level after transfection of psi-Survivin, pGRIM-19 and pGRIM-19- siRNA- Survivin plasmids, but GRIM-19 gene and protein levels in pGRIM-19 and pGRIM -19-siRNA-Survivin groups were upgegulated. proliferation inhibiting experiments showed that co-expression plasmid pGRIM-19-siRNA-Survivin inhibited cell growth better than single gene therapy group; FCM and Annexin V-FITC Detection: In psi-Survivin, pGRIM-19 and pGRIM-19-siRNA-Survivin groups, G1 phase arrest and apoptosis cells were observed, in co-expression pGRIM-19-siRNA-Survivin plasmid group there was more obvious G1 phase arrest cells and apoptosis cells; acridine orange and TUNEL staining found: co-expression plasmid could promote apoptosis significantly. immunofluorescence results found Survivin gathered in nucleus and the cytoplasm around in the transfected psi-Survivin, PGRIM-19 and pGRIM-19-siRNA-Survivin groups; RT-PCR and Western methods further revealed the pGRIM-19-si-Survivin expression plasmid could downgegulated Stat3, c-Myc, cyclinD1, BcL-xL expression while increased of the expression of caspase3.
1.3.4 Results in vivo: In order to observe the anti-prostate cancer effects of pGRIM-19-si-Survivin recombinant plasmid in vivo, the subcutaneous xenografts were constructed in nude mice. The recombinant bacteria carrying various plasmids were injected into intraperitoneal cavity into the tumor. The results once again proved that si-Survivin and GRIM-19 could inhibit the prostate cancer xenografts growth with synergism. Compared with the two single gene therapy groups,the mean tumor weight and mean tumor volume were lower, the tumor cells occurred apoptosis obviously through HE and TUNEL staining in Attenuated Salmonella typhi carrying pGRIM-19-si- Survivin plasmid group. The total RNA and proteins were extracted and the related genes and proteins were detected by semi-quantitative RT-PCR and Western blot. The results found that the co-expression plasmid inhibited prostate xenografts growth by downregulating Stat3, c-myc, cyclin D1,BcL-xL and VEGF but upregulating caspase3
1.4 Conclusion:
1.4.1 The co-expression pGRIM-19-si-Survivin plasmid showed synergic anti tumor effect not only for hormone-independent DU145 prostate cancer cells in vitro but also for the subcutaneous xenografrs of prostate cancer constructed with DU145 cells in vitro.
1.4.2 The main anti-tumor mechanism of the co-expression pGRIM-19-si-Survivin plasmid was to promote prostate cancer cells apoptosis.
1.4.3 The main barrier of gene therapy is that recombinant plasmid could not penetrate cell membrane by itself. Application of attenuated Salmonella typhi as the delivery of co-expression plasmid gene therapy vector has solved the problem.
RNAi technology is a revolutionary event at the end of the 20th century. We applied Attenuated Salmonella typhi usually used with oral vaccine as carrier for co-expression pGRIM-19-si-Survivin plasmid for prostate cancer xenografts therapy and found that the co-expression had strong anti tumor effect whether in vitro or in vivo. The above results showed the advanced, feasible and original research work.
2. Organic selenium inhibiting the relapse of androgen independence prostate cancer
Prostate cancer is a leading cause of cancer-related deaths in the Western countries, and in China, the incidence and mortality rates of prostate cancer have increased markedly because of aging population, lifestyle and dietary changing. Men currently diagnosed at the early stages of prostate cancer can, in many cases, be effectively treated by radiation, chemotherapy and endocrine therapy. However, in half of the patients, the disease will recur and ultimately develop into hormone-refractory prostate cancer and metastatic prostate cancers that are essentially incurable. New treatment of tumor therapy is thought highly of increasingly.
Selenium (Se) is an essential trace element with important biological functions. Studies have shown that selenium compounds inhibit the growth of prostate cancer cells, including the androgen-dependent LNCaP line and the androgen-independent PC-3 and DU145 lines in vitro. The growth inhibition is mediated by apoptosis induction. Selenium was able to significantly down regulate prostate-specific antigen (PSA) transcript and protein expression in the androgen-responsive LNCaP cells. Selenium also suppressed the binding of AR to the androgen responsive element site. Selenium intervention strategy aimed at toning down the amplitude of androgen signaling could be helpful in controlling morbidity or delaying the genesis of androgen independent prostate cancer.
2.1 Objective:
To investigate the effects and relative mechanisms that organic seleum postponing androgen inednpence prostatecancer.
2.2 Methods:
2.2.1. study In vitro
The prostate cancer cell lines LNCaP was treated with different doses of MSA, to determine the expression levels of PSA and AR, the semi-quantitative RT-PCR and Western blot analysis with the samples extracted from treated and control cells were performed. The detection for the inhibition of cell proliferation by SRB; the LNCaP cells were analyzed for apoptosis rate and cellular cycles by flow cytometry, the effect of MSA on Stat3 by immunocytochemistry and immunofluorescence.
2.2.2. study In vivo:
To study the effects of selenium treatment on prostate tumor with castration in vivo, nude mice were imbeded with androgen-dependence prostate cancer LNCaP mass to establish prostate cancer xenografts subcutaneously. Once the tumors reached adequate volumes the mice were operated with castration. At the same time a dose of 0 or 100μg/20g/day by oral gavage for 16 weeks. Tumor measurements were taken once a week. The growth rate and final weight of the tumors were recorded and compared between groups. In addition, the morphology changing and apoptotic cells were determined by HE and TUNEL assays. Immunohistochemical staining for AR, Stat3 and Hif-1αwere performed to determine the distribution and levels. In addition, RT-PCR and Western blot analysis were used to detect the expression levels of related genes and proteins. PSA concentration in serum was detected through ELASIA assay.
2.3 Results:
2.3.1 Results in vitro: The results from semi-quantitative RT-PCR and Western blot analyses for the LNCaP cell samples treated with different doses of MSA could specifically reduce AR and PSA expressions. The results of SRB demonstrated that cell proliferation was inhibited with time and dose dependence. MSA could promote LNCaP cells apoptosis by FCM analysis, MSA also could doweregulate Stat3 expression by immunocytochemistry and immunofluorescence significantly.
2.3.2 Results vivo: We copied the prostate cancer xenograft model with relapse after castration in vivo the results showed that in MSC group the average weights and volumes of the tumors were lower than controlled group. The tumor cells from MSC group had more significant apoptotic cells and lower proliferation rate. The expression of PSA, AR, Stat3 and Hif-1αwere down regulated by RT-PCR, Western and immunohistochemisty. ELASIA assay results showed that MSC could decrease the level of PSA in serum.
2.4 Conclusions:
MSA could inhibit androgen dependence prostate cancer LACaP cell proliferation and promote the cell apoptosis in vitro, mechanism might be related with downregulated AR expression. We constructed the relapse model of prostate cancer after castration in nude mouse successuly and found that organic seleum could postpone the relapse of androgen indepence prostate cancer induced by castration, the mechanism was related with that seleum inhibiting angiogenesis, reducing AR expression, inhibiting AR signal transduction and PSA secreation and downregulating HIF-1αand Stat3 expression.100μg/20g MSC didn’t manifest obvious side effects through oral administration. The technology roadmap and experimental results have not been reported till now at home and abroad.
目的: (1)通过体内外实验探讨pGRIM-19-si-Survivin共表达质粒抗前列腺癌作用与机制;探讨减毒沙门氏菌作为该共表达质粒运载体进行体内实验的可行性。(2)在成功建立去势后复发型前列腺癌模型的基础上,探讨甲基硒代半胱氨酸(MSC)抑制激素非依赖性前列腺癌的发生并探讨相关机制。
方法:(1)应用脂质体法将pGRIM-19-si-Survivin共表达质粒及对照质粒转染至人前列腺癌细胞DU145内,通过MTT法检测细胞增殖抑制情况,流式细胞术等观察细胞周期与凋亡,以RT-PCR、Western blot法检测目的基因与相关基因和蛋白的表达;复制裸鼠前列腺癌皮下移植瘤模型,腹腔注射携带pGRIM-19-si-Survivin共表达质粒等的减毒沙门氏菌,进行抗肿瘤作用与机制的研究。(2)复制裸鼠前列腺癌去势后复发模型,观察MSC对前列腺癌雄激素依赖性的影响。.
结果:(1)通过体内外实验证明pGRIM-19-si-Survivin共表达质粒的抗前列腺癌作用优于单基因治疗组,显示出明显的协同效应:①增殖抑制实验结果显示,共表达质粒显著地抑制DU145细胞的增殖活性;②流式细胞术和Annexin V-FITC等检测分析发现:共表达质粒的促凋亡作用最为显著;③DU145细胞的免疫荧光染色显示Survivin的表达聚集在细胞核及其周围的胞浆中;④共表达质粒组Stat3、c-Myc、cyclinD1、BcL-xL和VEGF基因和蛋白表达明显抑制,而caspase3的基因与蛋白表达显著上调。体内实验证明,携带pGRIM-19-si-Survivin共表达质粒的减毒沙门氏菌治疗组的抗肿瘤作用最明显,主要是通过促凋亡作用实现的;(2)MSA体外可抑制人激素依赖性前列腺癌LNCaP细胞的增殖并降低雄激素受体表达;MSC可抑制去势诱导的激素非依赖性前列腺癌的发生。
结论:减毒沙门氏菌携带pGRIM-19-si-Survivin共表达质粒,在抗前列腺癌作用中显示明显的协同作用;MSC可抑制去势诱导的激素非依赖性前列腺癌的发生。本研究所采用的技术路线及实验结果在国内外均未见报道。
1 Attenuated Salmonella typhi carrying theplasmid-co-expressed GRIM-19 and Survivin-specific shRNA for prostate cancer therapy
Prostate cancer is a common malignant tumor which is harmful to male of middle and old age. There is no ideal treatment except early prostate cancer could be effectively treated by radical operation. A high degree of malignant prostate cancer tends to micrometastasis earlier. So it is very significant to search the candidate which is no toxic but effective. RNA interference (RNA interference, RNAi) technology was a great discovery and had been used for the treatment of many diseases at the end of the 20th century in academic medicine. The main material of RNAi is the long double strand RNA (dsRNA), when it goes into the cell it is cleavaged into short dsRNAs with 21-23 nucleotides which are called siRNA (small interfering RNA also called short double-stranded RNA), siRNA is a sequence-specific post-transcriptional gene silencing mechanism, which is triggered by double-stranded RNA (dsRNA) and causes degradation of mRNA homologous in sequence to the dsRNA. This new approach has been successfully adopted to inhibit tumorigenicity. RNAi technology is currently being evaluated not only as an extremely powerful instrument for functional genomic analyses, but also as a potentially useful method to develop specific dsRNA based gene-silencing therapeutics.
The target gene-specific siRNA preparation method:①Chemical synthesis: this type of siRNA goes into the cell directly and plays a key role but with high price, easily degradated and short half-life;②Preparation of siRNA recombinant plasmid: Endogenous delivery is possible by inserting DNA templates for siRNAs into RNA polymeraseⅢ(polⅢ) transcription units, which are based on the sequences of the natural transcription units of the small nuclear RNA U6 or the human RNase P RNA H1. the approach is available for expressing siRNAs with stability. With the development of the RNAi technology and deeper understanding of this field, a promising new modality of treatment appeared, which can be used in combination with the existing therapies for prostate cancer therapy.
We based on the fact that the siRNA-Survivin had significant role in inhibiting the growth of prostate cancer. In order to improve its anti tumor effect we took the cell death regulator GRIM-19 (gene associated with retinoid-IFN-induced mortality19, to construct pGRIM-19-siRNA -Survivin co-expression plasmid and explore its synergistic anti-prostate cancer effect.
Recombinant plasmid carrier research: RNAi technology drug is highly efficient, very small amounts of RNAi inducer could make specific target genes silence, reverse the malignant phenotype of tumor cells and induce apoptosis of tumor cells. However, the recombinant plasmid expressing siRNA can not penetrate cell membrane. The delivery of RNAi effector to target cells is one of the key factors determining therapeutic efficacy, because gene silencing is limited to cells reached by RNAi effectors. The biggest challenge is how to solve the carrier. In recent years, studies have demonstrated that attenuated Salmonella typhi has tropic-tumor activity. The preliminary research confirmed that the attenuated Salmonella typhi had gathered in solid tumor. Compared with normal tissue, the reproductive advantage was more than 1,000 times. In addition, it not only grew in severe hypoxia of solid tumors but also in the micrometastasis tumor, and had the effect of tumor lysis. In particular, attenuated Salmonella typhi (Ty21a) as an oral vaccine carrier have been used for 25-year in clinic. Therefore, this article selected attenuated Salmonella typhi as carrier for pGRIM-19-siRNA-Survivin recombinant plasmid for the delivery of anti-prostate cancer research.
1.1 Objective:
Attenuated Salmonella typhi carrying pGRIM-19-siRNA-Survivin co-expression plasmid as delivery vector for anti-prostate cancer research was applied. The aim is to explore the pGRIM-19-siRNA-Survivin expression plasmid whether or not had synergic effect in the role of anti-prostate cancer and confirm the feasibility of Attenuated Salmonella typhi as delivery for prostate cancer xenografts therapy.
1.2 Methods:
1.2.1 pGRIM-19-siRNA-Survivin expression vector constructed successfully: As psi-Survivin plasmid as a template, PCR was applied for amplification of U6 promoter and the psi-Survivin sequence, then the PCR products were cloned into the pGRIM-19 eukaryotic expression vector to construct the co-expression pGRIM-19 -siRNA-Survivin plasmid which at the same time expresses si-Survivin and GRIM-19 gene
1.2.2 Studies In vitro:
Human androgen-independent DU145 prostate cancer cell lines were used for the project, recombinant plasmids were transfected into cells with lipofection. Cell proliferation was detected by MTT at different time; cell cycle and apoptosis were detected through flow cytometry (FCM), Annexin V-FITC kit, acridine orange staining and Tunel method. Survivin protein distribution with immunofluorescent staining ; the target gene and protein (Survivin, GRIM-19) and associated genes and protins (Stat3, c-Myc, CyclinD1, BcL-xL, caspase3 and VEGF) expressions by RT– PCR and Western blot
1.2.3 Studies in vivo:
In order to observe the anti-prostate cancer effect of the recombinant plasmids, we constructed nude prostate cancer xenografts hypodermically and injected Attenuated Salmonella typhi carrying different plasmids into peritoneal cavity to the tumor. We measured tumor volumes, compared tumor growth rates and tumor weights between groups at the same time. RT-PCR, Western blot and immunohistochemical staining were used to detect the target genes and proteins and associated genes and proteins (Stat3, c-Myc, cyclinD1, BcL-xL, caspase3 and VEGF); HE and TUNEL staining of tumor tissue for were used to detect the changes in morphology and apoptosis. Through the assays we evaluated the anti-prostate cancer effects and revealed the related mechanisms of the co-expression plasmid.
1.3 Results:
1.3.1 RT-PCR, immunohistochemistry and Western blot results showed that: gene and protein expressions of Survivin in prostate cancer and DU145 cells were significantly higher than that of normal prostate tissue, while the expressions of GRIM-19 significantly lower than normal prostate tissue.
1.3.2 We successfully constructed the co-expression pGRIM-19-siRNA-Survivin plasmid identified by restriction enzyme digestion and sequencing which has two promoters and expresses si-RNA-Survivin and GRIM-19 at the same time.
1.3.3 Results In vitro: the Survivin expression was dowenregulated in gene and protein level after transfection of psi-Survivin, pGRIM-19 and pGRIM-19- siRNA- Survivin plasmids, but GRIM-19 gene and protein levels in pGRIM-19 and pGRIM -19-siRNA-Survivin groups were upgegulated. proliferation inhibiting experiments showed that co-expression plasmid pGRIM-19-siRNA-Survivin inhibited cell growth better than single gene therapy group; FCM and Annexin V-FITC Detection: In psi-Survivin, pGRIM-19 and pGRIM-19-siRNA-Survivin groups, G1 phase arrest and apoptosis cells were observed, in co-expression pGRIM-19-siRNA-Survivin plasmid group there was more obvious G1 phase arrest cells and apoptosis cells; acridine orange and TUNEL staining found: co-expression plasmid could promote apoptosis significantly. immunofluorescence results found Survivin gathered in nucleus and the cytoplasm around in the transfected psi-Survivin, PGRIM-19 and pGRIM-19-siRNA-Survivin groups; RT-PCR and Western methods further revealed the pGRIM-19-si-Survivin expression plasmid could downgegulated Stat3, c-Myc, cyclinD1, BcL-xL expression while increased of the expression of caspase3.
1.3.4 Results in vivo: In order to observe the anti-prostate cancer effects of pGRIM-19-si-Survivin recombinant plasmid in vivo, the subcutaneous xenografts were constructed in nude mice. The recombinant bacteria carrying various plasmids were injected into intraperitoneal cavity into the tumor. The results once again proved that si-Survivin and GRIM-19 could inhibit the prostate cancer xenografts growth with synergism. Compared with the two single gene therapy groups,the mean tumor weight and mean tumor volume were lower, the tumor cells occurred apoptosis obviously through HE and TUNEL staining in Attenuated Salmonella typhi carrying pGRIM-19-si- Survivin plasmid group. The total RNA and proteins were extracted and the related genes and proteins were detected by semi-quantitative RT-PCR and Western blot. The results found that the co-expression plasmid inhibited prostate xenografts growth by downregulating Stat3, c-myc, cyclin D1,BcL-xL and VEGF but upregulating caspase3
1.4 Conclusion:
1.4.1 The co-expression pGRIM-19-si-Survivin plasmid showed synergic anti tumor effect not only for hormone-independent DU145 prostate cancer cells in vitro but also for the subcutaneous xenografrs of prostate cancer constructed with DU145 cells in vitro.
1.4.2 The main anti-tumor mechanism of the co-expression pGRIM-19-si-Survivin plasmid was to promote prostate cancer cells apoptosis.
1.4.3 The main barrier of gene therapy is that recombinant plasmid could not penetrate cell membrane by itself. Application of attenuated Salmonella typhi as the delivery of co-expression plasmid gene therapy vector has solved the problem.
RNAi technology is a revolutionary event at the end of the 20th century. We applied Attenuated Salmonella typhi usually used with oral vaccine as carrier for co-expression pGRIM-19-si-Survivin plasmid for prostate cancer xenografts therapy and found that the co-expression had strong anti tumor effect whether in vitro or in vivo. The above results showed the advanced, feasible and original research work.
2. Organic selenium inhibiting the relapse of androgen independence prostate cancer
Prostate cancer is a leading cause of cancer-related deaths in the Western countries, and in China, the incidence and mortality rates of prostate cancer have increased markedly because of aging population, lifestyle and dietary changing. Men currently diagnosed at the early stages of prostate cancer can, in many cases, be effectively treated by radiation, chemotherapy and endocrine therapy. However, in half of the patients, the disease will recur and ultimately develop into hormone-refractory prostate cancer and metastatic prostate cancers that are essentially incurable. New treatment of tumor therapy is thought highly of increasingly.
Selenium (Se) is an essential trace element with important biological functions. Studies have shown that selenium compounds inhibit the growth of prostate cancer cells, including the androgen-dependent LNCaP line and the androgen-independent PC-3 and DU145 lines in vitro. The growth inhibition is mediated by apoptosis induction. Selenium was able to significantly down regulate prostate-specific antigen (PSA) transcript and protein expression in the androgen-responsive LNCaP cells. Selenium also suppressed the binding of AR to the androgen responsive element site. Selenium intervention strategy aimed at toning down the amplitude of androgen signaling could be helpful in controlling morbidity or delaying the genesis of androgen independent prostate cancer.
2.1 Objective:
To investigate the effects and relative mechanisms that organic seleum postponing androgen inednpence prostatecancer.
2.2 Methods:
2.2.1. study In vitro
The prostate cancer cell lines LNCaP was treated with different doses of MSA, to determine the expression levels of PSA and AR, the semi-quantitative RT-PCR and Western blot analysis with the samples extracted from treated and control cells were performed. The detection for the inhibition of cell proliferation by SRB; the LNCaP cells were analyzed for apoptosis rate and cellular cycles by flow cytometry, the effect of MSA on Stat3 by immunocytochemistry and immunofluorescence.
2.2.2. study In vivo:
To study the effects of selenium treatment on prostate tumor with castration in vivo, nude mice were imbeded with androgen-dependence prostate cancer LNCaP mass to establish prostate cancer xenografts subcutaneously. Once the tumors reached adequate volumes the mice were operated with castration. At the same time a dose of 0 or 100μg/20g/day by oral gavage for 16 weeks. Tumor measurements were taken once a week. The growth rate and final weight of the tumors were recorded and compared between groups. In addition, the morphology changing and apoptotic cells were determined by HE and TUNEL assays. Immunohistochemical staining for AR, Stat3 and Hif-1αwere performed to determine the distribution and levels. In addition, RT-PCR and Western blot analysis were used to detect the expression levels of related genes and proteins. PSA concentration in serum was detected through ELASIA assay.
2.3 Results:
2.3.1 Results in vitro: The results from semi-quantitative RT-PCR and Western blot analyses for the LNCaP cell samples treated with different doses of MSA could specifically reduce AR and PSA expressions. The results of SRB demonstrated that cell proliferation was inhibited with time and dose dependence. MSA could promote LNCaP cells apoptosis by FCM analysis, MSA also could doweregulate Stat3 expression by immunocytochemistry and immunofluorescence significantly.
2.3.2 Results vivo: We copied the prostate cancer xenograft model with relapse after castration in vivo the results showed that in MSC group the average weights and volumes of the tumors were lower than controlled group. The tumor cells from MSC group had more significant apoptotic cells and lower proliferation rate. The expression of PSA, AR, Stat3 and Hif-1αwere down regulated by RT-PCR, Western and immunohistochemisty. ELASIA assay results showed that MSC could decrease the level of PSA in serum.
2.4 Conclusions:
MSA could inhibit androgen dependence prostate cancer LACaP cell proliferation and promote the cell apoptosis in vitro, mechanism might be related with downregulated AR expression. We constructed the relapse model of prostate cancer after castration in nude mouse successuly and found that organic seleum could postpone the relapse of androgen indepence prostate cancer induced by castration, the mechanism was related with that seleum inhibiting angiogenesis, reducing AR expression, inhibiting AR signal transduction and PSA secreation and downregulating HIF-1αand Stat3 expression.100μg/20g MSC didn’t manifest obvious side effects through oral administration. The technology roadmap and experimental results have not been reported till now at home and abroad.
引文
[1] Debatin KM. Apoptosis pathways in cancer and cancer therapy [J]. Cancer Immunof Immunother 2004,53(3):153-159.
[2] Crook NE, Clem RJ, Miller LK, et al. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif [J] . J Virol 1993, 67(4): 2168-2174.
[3] Nachmias B, Ashhab Y, Ben-Yehuda D, et al. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer[J]. Semin Cancer Biol 2004,14(4):231-243.
[4] Koike H, Sekine Y, Kamiya M, et al. Gene expression of Survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology. 2008, 72(6):1229-33.
[5] Jiang X, Wilford C, Duensing S, et al. Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells [J]. J Cell Biochem, 2001,83(2):342-354.
[6] Li F, Abmrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by Survivin [J]. Nature,1998,369 (6711): 580-584.
[7] Skoufias D A, Mollinari C Lacroix F B, et al. Human Survivin of apoptosis and mitotic spindle is a kinetochore-associated passenger protein [J]. J Cell Biol. 2000,151(7):1575-1582.
[8] Jiang X, Wilford C, Duensing S, et al. Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells [J]. J Cell Biochem,2001,83(2):342-354.
[9] Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with Survivin function [J].Nature Cell Biol,1999,1(8):461-466.
[10] Skoufias D A, Mollinari C Lacroix F B, et al. Human Survivin of apoptosis and mitotic spindle is a kinetochore-associated passenger protein [J]. J Cell Biol. 2000,151(7):1575-1582.
[11] Wheatley SP, Carvalho A, Vagnarelli P, et al. INCENP is required for proper targeting of Survivin to the centromeres and the anaphases pindle during mitosis[J]. Curr Biol, 2001,ll(11): 886-890.
[12] Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immuno- chemicallydistinct subcellular pools and is involved in spindle microtubule function[J].J Cell Sci. 2002,115(3):575-585.
[13] Lehner R, Bobak J, Kim NW, et al . Localization of telomerasehtert protein and Survivin in placenta: relation to placental development and hydatidiform mole[J]. Obstet Gynecol. 2001,97(6): 965-970.
[14] Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by Survivin predicts shorter survival rates in colorectal cancer[J]. Cancer Res. 1998, 58 (22):5071-5074.
[15] Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes [J]. Nat Genet. 1999,23 (4):387-388.
[16]张洪珍,段昕波,刘国魁,等.食管癌Survivin、血管内皮生长因子蛋白表达及临床意义[J].河北医科大学学报.2007,28(1):5-8. [ 17 ] Xu J H, Huang HZ, Pan CB, et al . Role of Survivin gene on the apoptosis of Tca8113 cells induced by cisplatin [J]. Hua Xi Kou Qiang Yi Xue ZaZhi.2007, 25 (2):173-176
[18] Zwicker J, Lucibello Fc, Wolfraim LA, et al. Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes based on a common mechanism of transcriptional repression [J]. EMBO J, 1995, 14(18): 4514-4522.
[19] Chiou SK, Jones MK, Tarnawski AS. Survivin—an antiapoptosis protei: its biological roles and implications for cancer and beyond [J]. Med Sci Monit 2003 , 9(4):125-129.
[20] Papapetropoulos A, Fulton D, Mahboubi K, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/Survivin pathway [J]. J Biol Chem. 2000, 275(13): 9102-9105.
[21] Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins Survivin and XIAP by VEGF in vascular endothelial cells [J]. Biochem Biophys Res Commun. 1999, 264 (3):781- 788.
[22] Kirkiles-Smith NC, Mahboubi K, Plescia J, et al. IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of Survivin expression[J]. J Immunol. 2004, 172(3):1391- 1396.
[23] Mahboubi K, Li F, Plescia J, et al. Interleukin-11 up- regulates Survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway [J]. Lab Invest. 2001, 81(3):327-334.
[24] Altznauer F, Martinelli S, Yousefi S, et al. Inflammation- associated cell cycle-independent block of apoptosis by Survivin in terminally differentiated neutrophils[J]. J Exp Med. 2004, 199(10):1343-1354.
[25] Das A, Tan WL, Teo J, et al. Expression of Survivin in primary glioblastomas.J Cancer Res Clin Oncol. 2002, 128 (6):302-306.
[26] Mirza A, McGuirk M, Hockenberry TN, et al. Human Survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway[J]. Oncogene, 2002, 21(17): 2613-2622.
[27] Hoffman WH, Biade S, Zilfou J T, et al. Transcriptional repression of the anti-apoptotic Survivin gene by wild type p53 [J]. J Bio1 Chem.2002, 277(5):3247-3257.
[28] Chao JI, Kuo PC, Hsu TS. Down-regulation of Survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells[J]. J Biol Chem, 2004 ,279(19): 20267-20276.
[29] Faqing T, Zhi H, Liqun Y, et al . Epstein-Barr virus LMP1 initiates cell proliferation and apoptosis inhibition via regulating expression of Survivin in nasopharyngeal carcinoma [J]. Exp Oncol, 2005,27(2):96-101.
[30] Islam A, Kageyama H, Hashizume K, et al. Role of Survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, Survivin-beta/2B[J]. Med Pediatr Oncol 2000,35(6):550–553.
[31] Hatori M, Sakamoto H, Satoh K, et al. DNA demethylase (dMTase) is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and Survivin genes exonl[J]. Cancer Lett, 2001,169(2):155-164.
[32]MillerLK. An exegesis of IAPS: salvationandsurprises from BIR motifs[J].Trends.Cell Biol,1999, 9(8):323-328.
[33] SunC, CaiM, Gunasekera AH, et al. NMR structure and mutagenesis of the inhibitor of apoptosis ptotein XIAP[J].Nature,1999, 401(6755):818-821.
[34] TammI, WangY, Sausville E, et al. IAP family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs [J]. CancerRes, 1998,58(23):5315-5320.
[35] Riedl SJ, Renatus M, Schwarzenbacher R, et al. Structural basis for the inhibitionof caspase3 byXIAP[J].Cell,2001,104(5):791-800.
[36] ShiY. Survivin structure: crystal unclear [J].Nat Struct Biol,2000;7(8):620 -623
[37] O’Connor DS, Grossman D, Plescia J, et al. Regulation of Apoptosis at cell division by p34cdc2 phosphorylation of Survivin[J]. Proc Natl Acad Sci USA. 2000,97(24):13103-13107.
[38] Du C, Fang M, Li L, et al. Smac mitochondrial protein that promotes cytochromec 2 dependent caspase activation by eliminating IAP inhibition [J]. Cell, 2000,102(1):33-42.
[39] Abrams J. An emerging blueprint for apoptosis in drosophila [J]. Trends Cell Biol. 1999,9 (11):435-40.
[40] Suzuki A, Ito T, KowanoH, et al. Survivin initiates procaspase3 Pp21 complex formation as a result of interaction withCdk4 to resist Fas mediated cell death [J]. Onco gene, 2000, 19(10):1346-1353.
[41] Fortugno P , Wall NR , Giodini A , et al . Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function[J ] .J Cell Sci,2002,115 (3):575—585.
[42] Chen J. Wu W Tahir SK, et al. Down-regulation of Survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth [J]. Neoplasia, 2000, 2(3):235-241.
[43] Suzuki A, Hayashida M, Ito T, et al. Survivin in initiates cell cycle entry by the competitive interaction with Cdk4/pl6(INK4a) and Cdk2/cyclin E complex activation[J]. Oncogene, 2000,19(29):3225-3234.
[44] Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death [J]. Oncogene, 2000, 19(10):1346–1353.
[45] O’Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of Survivin[J]. Proc Natl Acad Sci USA, 2000,97(24): 13103–13107.
[46] O’Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by Survivin expression in endothelial cells [J]. Am J Pathol, 2000,156:393–398,
[47] Mesri M, Wall NR ,Li J, et al . Cancer gene therapy using a Survivin mutant adenovirus [J]. J Clin Invest ,2001, 108(7): 981-990.
[48] Beierle EA, Nagaram A, Dai W, et al. VEGF-mediated Survivin expression in neuroblastoma cells[J]. J Surg Res. 2005,127(1):21-28.
[49] Beardsmore D M , Verbeke C S , Davies C LApoptotic and proliferative indexes in esophageal cancer : predictors of response to neoadjuvant therapy apoptosis and proliferation in esophageal cancer[J]. J Gastrointest Surg, 2003,7(1) :77–87.
[50] Zhang XY, Zhong L H, Hu K, et al . Expression of Survivin and it’s correlation with P53 in non small cell lung cancer [J]. Med J Wuhan University,2004,25 (3) :271–274.
[51] Meng H , Lu C , Mabuchi H , et al . Prognostic significance and different properties of Survivin splicing variants in gastric cancer [J].Cance Lett, 2004,216(2):147–155.
[52] Nakamura M, Tsuji N, Asanuma K, et al. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients [J]. Cancer Sci, 2004, 95(1):44 -51.
[53] Zhang M, Latham DE, Delaney MA, et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer [J]. Oncogene,2005,24(15): 2474–2482.
[54] Zhang M, Mukherjee N, Bermudez RS, et al. Adenovirus- mediated inhibition of Survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo [J]. Prostate, 2005, 64 (3):293–302.
[55] Li F. Role of Survivin in cancer chemoprevention [J]. Assay Des-Simply Sci,2005, 1(1):2–6.
[56] Li F, Ling X, Huang H, et al . Differential regulation of Survivin expression and apoptosis by vitamin D(3) compounds in two isogenic MCF-7 breast cancer cell sublines[J]. Oncogene,2005,24(8):1385–1395.
[57]Takamizawa S, Scott D, Wen J,et al. The Survivin: fas ratio in pediatric renal tumors. JPediat r Surg, 2001, 36 (1) : 37- 42.
[58] Xing N, Qian J, Bostwick D, etal. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein Survivin.Prostate, 2001,48 (1) :7- 15.
[59]Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol [J]. Cancer Res, 2004, 64 (1):337-346.
[60] Kishi H, Igawa M,Kikuno N. Expression of the Survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity andapoptosis[J]. Ology, 2004, 171(5):1855-1860.
[61] Shariat SF, Lotan Y, Saboorian H,et al.Survivin expression is associated with features of biologically aggressive prostate carcinoma[J]. Cancer, 2004, 100(4): 751-757.
[62] Fromont G, Chene L, Vidaud M, et al. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR[J]. Int J Cancer, 2005,114 (2):174–181.
[63] Kaur P, Kallakury BS, Sheehan CE, et al. Survivin and Bcl-2 expression in prostatic adenocarcinomas[J]. Arch Pathol Lab Med,2004,128(1): 39-43.
[64]高吴阳,胡传义,易慕华. Survivin蛋白在前列腺癌中的表达及其与肿瘤细胞凋亡的关系[J].中华男科学, 2004,10(1): 12-14.
[65]张向阳,曾强,齐范. Survivin蛋白在前列腺癌中的表达及其意义[J].中国现代医学杂志,2006,16(7):1060-1062.
[66]夏雪雁,李连宏,李先承.凋亡相关基因Survivin蛋白在前列腺癌组织中的表达及临床意义[J].大连医科大学学报,2006,28(4): 288-289
[67] Shapior GI. Preclinical and clinical development of t hecyclindependent kinase inhibitor flavopiridol [J] . Clin CancerRes, 2004 ,10 (12 Pt 2) :4270-4275. [ 68] Fulda S ,Debatin KM. Sensitization for tumor necrosis factor related apoptosis inducing ligand induced apoptosis by the chemopreventive agent resverat rol [ J ] . Cancer Res, 2004, 64(1):337-346.
[69]辛晓燕,袁鹏,黄艳红,等.染料木黄酮和顺铂对耐药卵巢癌细胞SKOV23中Survivin表达的影响[J].肿瘤,2007,27(1):13-15.
[70] Tu SP, Jiang XH, Lin MC, et al. Suppression of Survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer [J]. Cancer Res, 2003,63(22) :7724 -7732.
[71] Hague A, Eveson JW, MacFarlane M , et al . Caspase3 expression is reduced, in the absence of cleavage, in terminally differentiated normal oral epithelium but is increased in oral squamous cell carcinomas and correlates with tumour stage[J ] . J Pathol 2004, 204(2) :175-182
[72] Shen C, Duck A, Polat B, et al. Triplex forming cligodeoxy nucleotides targeting Survivin inhibitor proliferation and induce apoptosis of human lung carcinoma cells [J ] . Cancer Gene Ther, 2003,10(5) :403-410.
[73] Khanna N, Sen S, Sharma H, et al. S29 ribosomal protein induces apoptosis in H520 cells and sensitizes the mitochemotherapy [J ]. Biochem Biophys Res Commun, 2003,304(1):26-35.
[74] Fuessel S, Herrmann J, Ning S, et al. Chemosesitization of bladder cancer cells by Survivin2directed antisense oligodeoxynucleotides and siRAN [J].Cancer Lett ,2006,232(2) :243-254.
[75] Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity [J]. Anti-Cancer Drugs, 2004,15(5): 411-419.
[76] Gunawardena K, Camphbell LD, Meikle AW. Combination therapy with vitamins C plus E inhibits Survivin and human prostate cancer cell growth [J]. Prostate, 2004,59 (3) :319 -327.
[77] Griffith TS, Kemp TJ. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis [J]. Cancer Chemotherapy & Pharmacology, 2003,52(3): 175- 184.
[78]刘艳波,赵丽娟,赵丽晶等,Survivin-SiRNA对前列腺癌细胞PC-3M增殖的抑制作用.中国病理生理杂志,2008;24(10):1873-1876.
[79] Muenchen HJ, Poncza PJ, Pienta KJ. Different docetaxel- induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC -3[J]. Urology,2001 ,57(2) :366-370.
[80] Kalvakolanu DV. The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression [J]. Cytokine Growth Factor Rev, 2004, 15 (223):169-194.
[81] Chidambaramn V, Angell J E, Ling W, et al. Chromosomal localization of human GRIM-19, a novel IFN beta and retinoic acid activated regulator of cell death [J]. J Interferon Cytokine Res, 2000, 20 (7): 661-665.
[82] Angell JE, Lindner DJ, Shapiro PS, et al. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem, 2000, 275(43): 33416–33426.
[83] Hu J, Angell J E, Zhang J, et al. Characterization of monoclonal antibodies against GRIM-19, a novel IFN beta and retinoic acid activated regulator of cell death [J]. J Interferon Cytokine Res, 2002, 22 (10):1017-1026. [84 ] Huang G, Lu H, Hao A, et al. GRIM-19, a cell death regulatory protein, isessential for assembly and function of mitochondrial complex I[J]1Mol Cell Biol, 2004, 24 (19): 8447-8456. .
[85] Lufei C, Ma J, Huang G, et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction [J].EMBO J, 2003, 22 (6) : 1325-1335.
[86] Zhang X, Huang Q, Yang Z, et al. GW112, a novel anti-apoptotic protein that promotes tumor growth [J]. Cancer Res, 2004, 64 (7): 2474-2481.
[87] Kalakonda S, Nallar S C, Gong P, et al. Tumor suppressive protein gene associated with retinoid interferon induced mortality (GR IM) -19 inhibits src induced oncogenic transformation at multiple levels[J]. Am J Pathol, 2007, 171 (4):1352-1368.
[88] Kalakonda S, Nallar S C, L Indner D J, et al. Tumor suppressive activity of the cell death activator GRIM-19 on a constitutively active signal transducer and activator of transcription [J]. Cancer Res, 2007, 67 (13): 6212-6220.
[89] Zhang J, Yang J, Roy S K, et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription [J]. Proc Natl Acad Sci USA, 2003,100 (16): 9342-9347.
[90] Ma X, Kalakond A S, Srinivasula SM, et al. GRIM-19 associates with the serine protease HtrA2 for promoting cell death[J].Oncogene,2007, 26 (33): 4842-4849
[91] Rozan L M, Eldeiry W S. Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target [J].Cancer Biol Ther, 2006, 5(9) :1228-1235.
[92] Chen Y, Yuen W H, Fu J, et al. The mitochondrial respiratory chain controls intracellular calcium signaling and NFAT activity essential for heart formation in Xenopus laevi [J]. Mol Cell Biol, 2007, 27 (18) : 6420-6432.
[93] Huang G, Chen Y, Lu H, et al. Coup ling mitochondrial respiratory chain to cell death: an essential role of mitochondrial complexI in the interferon beta and retinoic acid induced cancer cell death [J]. Cell Death Differ,2007, 14 (2): 327-337.
[94] Barnich N, Hisamatsu T, Aguirre J E, et al. GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of antibacterial function in intestinal epithelial cells[J]. J Biol Chem, 2005, 280 (19): 19021-19026.
[95] Seo T, Lee D, Shim YS, et al. Viral interferon regulatory factor of Kaposi’s sarcoma associated herpes virus interacts with a cell death regulator, GRIM-19, and inhibits interferon/retinoic acid induced cell death[J]. J Virol, 2002, 76 (17): 8797-8807.
[96] Reevesm B, Daviesa A, Mcsharryb P, et al. Complex I binding by a virally encoded RNA regulates mitochondria induced cell death [J]. Science, 2007, 316 (5829):1345-1348
[97] Ling Z, Lifang G, Yang L, et al. Effects of Plasmid-Based Stat3-Specific Short Hairpin RNA and GRIM-19 on PC-3M Tumor Cell Growth Clin Cancer Res 2008, 14(2):559-568
[98] Papa F, Delia M, Trentadue R, et al. Differential effects of all trans retinoic acid on the growth of human keratinocytes and mouth carcinoma epidermoid cultures involvement of GRIM-19 and complex I of the respiratory chain [J]. Int J Immunopathol Pharmacol, 2007,20 (4): 719-729.
[99] Gong LB, Luo X L, Liu SY, et al. Correlations of GRIM-19 and its target gene product STAT3 to malignancy of human colorectal carcinoma [J]. Ai Zheng, 2007, 26(7): 683-687.
[100] Zhang X, Choem S, Lee JE, et al. GRIM-19 expression and its correlation with clinical outcomes of an induction chemotherapy for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN ) [J]. J Clin Oncol, 2005, 23(16s): 55191
[101] Montini E, Cesana D, SchmidtM, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vectorintegration [J]. Nature Biotechnol, 2006, 24 (6): 687-696.
[102] Blesch A. Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer [J]. Methods, 2004, 33 (2): 164-172.
[103] Taulli R, Accornero P, Follenzi A, et al. RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met -mediated tumor genesis [J]. Cancer Gene Ther, 2005, 12 (5) : 456-463.
[104] Bastone P, Romen F, LiuW, et al. Construction and characterization of effivcient, stable, and safe replication - deficient foamy virus vector [J]. Gene ther, 2007,14 (7): 613～620.
[105] Yant SR, Ehrhardt A, Mikkelsen JG, et al. Transposition from a gutless adeno -transposon vector stabilizes transgene expression in vivo [J]. Nature Biotechnol, 2002, 20 (10): 999-1005
[106] GoncalvesM A, van derVelde I, Knaan - Shanzer S, et al. Stable transduction of large DNA by high - capacity adeno associated virus / adenovirus hybrid vectors [J]. Virol, 2004, 321(2): 287-296.
[107] Vasileva A, Linden RM, Jessberger R. Homologous recombination is required for AAV - mediated gene targeting [ J ]. Nucleic Acids Res, 2006, 34 (11): 3345- 3360.
[108] Lai Y, Yue Y, Liu M, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors [J]. NatBiotechnol, 2005,23(11): 1435-1439.
[109] Guerra S, Lopez - Fernandez LA, Pascual - Montano A, et al. Host response to the attenuated poxvirus vector NYVAC: up regulation of apoptotic genes and NF-kappaB -responsive genes in infected HeLa cells[ J ]. J Virol, 2006, 80 (2): 985-998.
[110]Adusumilli PS, StilesBM, ChanMK, et al. Imaging and therapy of malignant pleural mesothelioma using replication– competent herpes simplex viruses [J]. J Gene Med, 2006, 8 (5): 603 -615.
[111]Shah K, Breakefield XO. HSV amplication vectors for cancer therapy [J]. Current Gen Thera,2006, 6 (3): 361-370.
[112] Timmerman JM, Singh G, Hermanson G, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B - cell lymphoma [J]. Cancer Res, 2002, 62 (20):584-552.
[113]Kim KS, Park YS. Antitumor effects of angiostatin K1-3 and endostatin genes coadministered by hytrodynamics-based transfection method[J]. Onco Res, 2005,15: 343～350.
[114]Serikawa T, Kikuchi A, Sugaya S, et al. In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy [J]. J Controlled Release, 2006, 113(3):255-260.
[115]Li WJ, Szoka FC. Lipid-based nanoparticles for nucleic acid delivery [J]. Pharmaceu res, 2007, 24 (3): 438-449.
[116] Chen J, Tian B, Yin X, et al. Preparation, characterization and transfection efficiency of cationic PEGylated PLA nanoparticles as gene delivery systems [J].J Biotechnol, 2007, 2(8):1166-1175.
[117]Kneuer C, Ehrhardt C, Bakowsky H, et al. The influence of physicochemical parameters on the efficacy of non - viral DNA transfection comp lexes: a comparative study [ J ]. J Nanosci Nanotechnol, 2006, 6 (9-10): 2776-2782.
[118]Liu G, LiD, PasumarthyMK, et al. Nanoparticles of compacted DNA transfect postmitotic cells [J]. J Biol Chem, 2003, 278(35): 32578-32586.
[119]Corsi K, Chellat F, Yahia L, et al. Mesenchymal stem cells,MG63 and HEK293 transfection using chitosan - DNA nanoparticles [J]. Biomaterials,2003, 24 (7):1255-1264.
[120]Ito A, Matsuoka F, Honda H, et al. Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma [ J ]. Cancer Immunol Immunother, 2004,53(1): 26-32.
[121]Iwasaki Y, Ueda M, Yamada T, et al. Gene therapy of liver tumors with human liver-specific nanoparticles [J]. Cancer Gene Ther, 2007,14 (1):74-81.
[122]Schatzlein A G. Non viral vectors in cancer gene therapy: principles and progress [J]. Anticancer Drugs, 2001, 12 (4) : 275-304.
[123] Gupta K, Zhang J. Angiogenesis: a curse or cure [J]. Postgrad Med J, 2005, 81 (954): 236-242.
[124]Nuyts S. Clostridium spores for tumor specific drug delivery [J].Anticancer Drugs, 2002, 13 (2):115-125.
[125]Liu S C, Minton N P, Giaccia A J, et al. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia necrosis[J]. Gene Therapy,2002, 9( 4):291-296.
[126] Yazawa K, Fuj IM , Amano J, et al. Bifidobacterium longum as a delivery system for cancer gene therapy:Selective localization and growth in hypoxic tumors [J]. Cancer Gene Therapy, 2000, 7(2):269-274.
[127]Yazawa K, Fujimor IM, Nakamura T, et al. Bifidobacteriumlongum as a delivery system for gene therapy of chemically induced rat mammary tumors[J]. Breast Cancer Res Treat, 2001, 66( 2):165-170.
[128]Vaupel PW. Oxygenation of solid tumors in drug resistance in oncology [P]. In: Teicher BA, ed. New York: Marcel Dekker, 1993: 532
[129]徐根兴.转人实体瘤内皮抑制因子( Endostatin)基因双歧杆菌的方法[J].发明专利公报,1999,15(20):20.
[130]Nakamura T, Sasaki T, Fujimor IM, et al. Cloned cytosine deaminase gene expression of Bifidobacterium longum and app lication to enzyme /prodrug therapy of hypoxic solid tumors[J]. Biosci Biotechnol Biochem, 2002, 66(11):2362-2366.
[131]Li XI, Fu GF, Fan YR, et al. Bifidobacterium adoles centis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth[J]. Cancer Gene Therapy, 2003,10(2):105-111.
[132]Kochi SK, Killeen KP, Pyan US, et al. Advance in the development of bacterial vector technology. Expert Rev Vaccine,2003,2(1):3d1-43.
[133]Figueroa-Bossi N, Uzzau S, Maloriol D, et al. Variable assortment of pathogenic determinants in Salmonella. Mol Microbiol, 2001, 39(2): 260-271.
[134]Platt J, Sodi S, Kelley M, et al. Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur J cancer, 2000, 36(18): 2397-2402
[135]Sznol M, Lin SL, Bermudes D, et al. Use of preferentially replicating bacteria for the treatment of cancer. J Clin invest, 2000, 105(8): 1027-1030.
[136]Ling Z, Lifang G, Lijuan Z, et al. Intratumoral Delivery and Suppression of Prostate Tumor Growth by Attenuated Salmonella enterica serovar typhi Carrying Plasmid-Based Small Interfering RNAs. Cancer Res. 2007,67(12):5859-5864.
[137]邵月婷,徐德启,刘亚男等.减毒沙门氏菌靶向携带共表达质粒p53/siRNA- Survivin抗前列腺癌的体内研究.中国肿瘤临床.2008,35(9): 527-529.
[138]Rubanyi GM. The future of human gene therapy [J]. Mol AspectsMed, 2001, 22 (3):113-142.
[139]Hirayama K, Rafter J. The role Probiotic bacteria in cancer prevention [J]. Microbes Infect, 2000, 2 (6): 681-686.
[140]Roller M, Pietro FA, Cadern IG, et al. Intestinal immunity of rats with colon cancer is modulated by oligofructose enrichedinulin combined with Lactobacillus rham nosus and B if idobacterium lactis[J]. Br J Nutr, 2004,92(6):931-938.
[141]Singh J, Rivenson A, Tomita M, et al. B if idobacterium longum,a lactic acid producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis [J].Carcinogenesis, 1997,18 (4): 833-841
[142] Jemal A, Thomas A, Murray T, et al. Cancer statistics 2002[J]. CA Cancer J Clin, 2002, 52(3): 181-182.
[143]Kuwahara M, Tochigi T, Kawamura S, et al. Mass screening for prostate cancer: a comparative study in Natori,Japan and Changchun,China[J]. Urology, 2003, 61(1): 137-141.
[144]张灵,计国义,李晓萌,等.前列腺癌集团检诊对临床前列腺癌诊断的影响[J].中华泌尿外科杂志, 2004,25(2):103-105.
[145] Rosa J, Canovas P, Islam A, et al. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle [J]. Mol Biol Cell, 2006, 17:1483–1493.
[146] Arvilommi H.selenium and immune functions in humans infect [J]. Immun, 1983, 41(1):185-189.
[147] Mantovani G, Maccio A, Madeddu C,et al. Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity[J]. J Exp Ther Oncol. 2004,4(1): 69-78.
[148]Fangusarol JR, Jiang Y, Caldas H, et al. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome[J]. British Journal of Cancer, 2005, 92(1): 359-365.
[149]Zhang L, Gao L, Li Y, Lin G, et al. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin Cancer Res. 2008, 14(2):559-568.
[150] Scheper MA, Nikitakis NG, Sauk JJ. Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.
[151]Theys J, Barbe S, Landuyt W, et al. Tumor-specific gene delivery using genetically engineered bacteria. Curr Gene Ther, 2003, 3(3): 207-221.
[152] Guo CC, Ding J, Pan BR, et al. Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhi as carrier. World J Gastroenterol, 2003, 9(6): 1191-1195.
[153]Forbes NS, Munn LL, Fukumura D, et al. Sparse initial entrapment of systemically injected Salmonella typhi leads to heterogeneous accumulation within tumors. Cancer Res, 2003, 63(17): 5188–5193.
[154] Invernizzi R, Travaglino E, Benatti C, et al. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia [J]. Eur J Haematol, 2006,76(6): 494-501.
[155] McEleny KR,Watson RW, Coffey RN,et al. Inhibitors of apoptosis proteins in prostate cancer cell lines[J]. Prostate, 2002, 51:133-140.
[156]邵月婷,张灵,汲坤等. GRIM-19基因的克隆及其对小鼠前列腺癌细胞株的促凋亡作用.《基础医学与临床》2008,28 (1):13-17.
[157] Zhang M, Ho A, Hammond EH, Suzuki Y, et al. Prognostic Value of Survivin in Locally Advanced Prostate Cancer: Study Based on RTOG 8610. Int J Radiat Oncol Biol Phys. 2008,30. [Epub ahead of print] .
[158] Kucukzeybek Y, Gul MK, Cengiz E, et al. Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of Survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. J Exp Clin Cancer Res. 2008, 27(1):37-47.
[159] Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998, 391:806-811.
[160] Bernstein E, Caudy AA, Hammond SM, et al . Role for a bidentate ribonuclease in the initiation step of RNA interference [J]. Nature 2001, 409(6818): 363-366.
[161] Elbashir SM, Harborth J, Tuschl T, et al . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J]. Nature, 2001, 411 (6836): 494-498.
[162] Lewis D , Hagstrom J E, Loomis AG, et al. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice [J]. Nat Genet, 2002, 32 (1): 107-108.
[163] Fuessel S, Herrmann J, Ning S, et al. Chemosensitization of bladder cancer cells by Survivin-directed antisense oligodeoxynucleotides and siRNA [J]. Cancer Lett. 2006, 232:243-254.
[164]金冬雁译.克隆化基因在哺乳动物培养细胞中的表达[A].见J.萨姆布鲁克主编.分子克隆实验指南[M].第二版.北京:科学出版社. 1992,775-776.
[165] Li F,Ling X. Survivin Study: An Update of“What is the next wave?”[J]. J Cell Physiol, 2006, 208(1):476-486.
[166]Sudhakar Kalakonda, Shreeram C. Nallar, Ping Gong, et al. Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19inhibits src-induced oncogenic transformation at multiple levels The American Journal of Pathology, 2007,171(4): 1352-1368.
[167] Ma X, Kalakonda S, Srinivasula S M, et al. GR IM-19 associates with the serine protease HtrA for promoting cell death[ J ]Oncogene, 2007, 26 (33) :4842-4849.
[168]Alchanati I, Nallar SC, Sun P, et al. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Adv Anat Pathol. 2008, 15(1):46-53.
[169]Cheng chen Lufei, Jing Ma, et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. The EMBO Journal. 2003,22( 6 )1325-1335.
[170]Chen CL, Cen L, Kohout J,et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008, 21(7)78-86.
[171]Chelur DS, Chalfie M. Targeted cell killing by reconstituted caspase3. Pro Natl Acad Sci USA. 2007, 104(7):2283-2288.
[172] Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol, 2002, 3(9): 651-662.
[173] Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res, 2000, 60(14): 3689-3695.
[174] Jain N, Zhang T, Fong SL, et al. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene, 1998, 17(24): 3157-3167
[175] Nagy B, Szendroi A, Romics I. Overexpression of CD24, c-myc and Phospholipase 2A in Prostate Cancer Tissue Samples Obtained by Needle Biopsy.. Pathol Oncol Res. 2008 Aug 28. [Epub ahead of print] .
[176] Lee JG, Zheng R, McCafferty-Cepero JM,et al. Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Mol Carcinog. 2009, 48(2):141-149.
[177] Chen N, Chen X, Huang R, et al. BcL-xL is a target gene regulated by hypoxia-inducible factor-1-alpha. J Biol Chem. 2009 Feb 10. [Epub ahead of print].
[178] Li X, Marani M, Mannucci R, et al. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res 2001, 61: 1699-1706.
[179]Wang X, Zhang J, Kim HP, et al. BcL-xL disrupts death-inducing signal complex formation in plasma membrane induced by hypoxia/reoxygenation. FASEB J 2004, 18:1826-1833.
[180] Gabriel B, Sureau F, Casselyn M, et al. Retroactive pathway involving mitochondria in electroloaded cytochrome c-induced apoptosis. Protective properties of Bcl-2 and BcL-xL. Exp Cell Res 2003, 289: 195-210.
[181]Breckenridge DG, Xue D. Regulation of mitochondrial membrane permeabilization byBCL-2 family proteins and caspases. Curr Opin Cell Biol 2004, 16: 647-652.
[182] Bubendorf L, Sauter G, Moch H, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol, 1996, 178(4): 437-441.
[1] Schroder F, Walsh PC, Retik AB, et al. Hormonal therapy of prostate cancer.[M] Campbellps Urology. 8th ed. Philadelphia: W. B. Saunders Company, 2002, 3182-3208.
[2] Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. [J]. Urology, 2000, 56(6): 1021-1024.
[3] Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. [J].Cancer Res, 2002, 67 (2 Pt 2):948-951.
[4]鲍镇美.晚期前列腺癌的治疗新动向[J].中华泌尿外科杂志,2000,23(2): 69-72.
[5]应俊,姚德鸿,任晓敏.前列腺癌去势术前后雄性激素变化的研究[J].中华男科学,2003,6 (3):191～196.
[6]夏同礼.前列腺癌的基础与临床[M].北京:科学出版社,2000.227～238.
[7] Jiang W, Jiang C, Pei H, In vivo molecular mediators of cancer growth suppression and apoptosis by selenium in mammary and prostate models: lack of involvement of gadd genes. Mol Cancer Ther. 2009 Mar 10. [Epub ahead of print].
[8] Connell JM, Kir- by R, Connell J M, et al. 5 Alpha2 reductase in prostate disease[A]. Textbook of prostatic hyperplasia [M]. London: ISIS Medical Media. 1996, 85～90.
[9] Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects[J]. J Urol. 2001, 166(2):500～506.
[10]Oh WK. The evolving role of estrogen therapy in prostate cancer[J]. Clin Prostate Cancer, 2002, 1(2):81-89.
[11]Hedlund PO, Ala-opas M, Brekkan E , et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer- scandinavian prostatic cancer group(SPCG) study No. 5 [J]. Scand J Urol Nephrol, 2002, 36(6):405-143.
[12]Klotz L, McNeill I, Fleshner N. A phase 1 - 2 trial of diethylstilbestrol plus lowdose warfarin in advanced prostate carcinoma [J].J Urol. 1999, 161(1): 169-172.
[13]Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer [J]. Eur Urol, 2006, 49(1): 54-58.
[14]Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leup rolide plus daily antiandrogen in men with prostate cancer [J]. J Urol, 2002, 167(4):1670- 1674.
[15] Moffat LE. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer [J]. Eur Urol, 1990, 18 (3):26-27.
[161]Schroder FH, Whelan P, DeReijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the“European organization for research and treatment of cancer”(EORTC) protocol 30892 [J]. Eur Urol, 2004, 45(4):457-464.
[17]Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity [J]. J Urol, 1996, 155(1): 209-212.
[18]Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up[J]. J Urol, 2000, 164(5): 1579-1582.
[19]Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma[J]. Cancer, 2002, 5(2):361-376.
[20]Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review [J]. Urology, 2001, 7(4):727-732.
[21] Blackard CE, Byar DP, Jordan WP. Orchiectomy for advanced prostatic carcinoma. A reevaluation [J].Urology,1973, 1(6):553-560.
[22]Byar D P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. [J]. Cancer, 1973, 32(5):1126-1130.
[23] Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. [J].BrJ Urol, 1997, 79(2):235-246.
[24]Messing EM, Manola J, SarosdyM, et al. Immediate hormonal therapy comparedwith observation after radical prostatectomy in men with node positive prostate cancer [J]. N Engl J Med, 1999, 341(24): 1781-1788.
[25] Schulman CC, Debruyne FM, Forster G, et al. 42Year follow– up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2 - 3N0M0 prostate cancer. European study group on neoadjuvant treatment of prostate cancer [J]. Eur Urol, 2000, 38(6):706-713.
[26] Reese D M. Choice of hormonal therapy for prostate cancer [J]. Cancer, 2000, 355(9214):1473-1475.
[27] Shenk JL, Fisher CJ, Chen SY, et al. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 2001; 276(42): 38472-38479.
[28] Fujimoto N, Yeh S, Kang HY, et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate J Biol Chem 1999, 272(12): 8316-8321.
[29] Linja MJ, Savinainen KJ , Saramaki OR , et al.Amplification and overexpression of androgen receptor gene inhormone refractory prostate cancer. Cancer Res, 2001, 61 (9) : 3550-555.
[30] Taplin ME , Balk SP. Androgen receptor : A key moleculein the progression of prostate cancer to hormone independence. J Cell Biochem, 2004 , 91 (3) : 483-490.
[31] Lin MF, Meng TC, Rao PS, et al. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998; 273(10), 5939-5947.
[32] Culig Z, Hobisch A, Hittmair A. et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma Prostate 1998,35 (1): 63-70
[33]Brown RS, Edwards J, Dogan A, et al. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer J Pathol 2002, 198(2): 237-244.
[34] Koivisto P. Aneuploidy a nd rapid cell p rolif eration in recurrent prostate cancers with androgen receptor gene amplification [J], Prostate Cancer Prostatic Dis, 1997, 1(3):21-25.
[35] Edwards J, Krishna NS, Grigor KM, et al. Androgen receptor gene amplification and protein expression in hormone refrectory prostate cancer [J]. Br J Cancer,2003, 89(3):552-556.
[36]Chmelar R, Buchanan G, Need EF, et al . Androgen receptor coregulators and their involvement in the development and progression of prostate cancer [J]. Int J Cancer, 2007, 120 :719-733.
[37] Gregory CW, He B, Raymond T, et al. A mechanism for androgen receptor mediated prostate cancer recurrence after androgen deprivation therapy [J]. Cancer Res, 2000, 161(11): 4315-4319.
[38]Shen MM, Abate Shen C. Pten inactivation and the emergence of androgen independent prostate cancer [J]. Cancer Res, 2007, 67(14):6535-6538.
[39]Liao G, Chen LY, Zhang A, et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMR T [J].J Biol Chem,2003,278(7):5052-5061.
[40]Shenk JL, Fisher CJ, Chen S Y, et al. p53 represses androgen induced transactivation of prostate specific antigen by disrupting hAR amino to carboxylterminal interaction [J]. J Biol Chem, 2001, 276(42):38472-38479.
[41] Gurova KV, Roklin OW, Krivokrysenko V, et al. Expression of prostate specific antigen is negatively regulated by p53[J]. Oncogene, 2002, 21(1):153-157.
[42]Burchardt M, Burchardt T, Shabsigh A, et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells [J]. Prostate, 2001, 48(4):225-230.
[43] Corcoran NM, Costello AJ . Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer BJU Int, 2003, 91 (6): 545-553.
[44] Gioeli D , Ficarro SB , Kwiek JJ , et al . Androgen receptorphosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem, 2002, 277 (32 ) :29304-29314.
[45]Murtha PE, Zhu W, Zhang J , et al . Effects of Ca2 + mobilization on expression of androgen regulated gene: interference with androgen receptor mediated transactivation by AP21 proteins. Prostate, 1997 , 33 : 264-270.
[46] Cronauer MV, Schulz WA , Burchardt T , et al . The androgen receptor in hormone refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol, 2003, 23 (4): 1095-10102.
[47] Murillo H , Schmidt LJ , Tindall DJ , et al . Tyrphostin AG825 triggers p38 mitogen-activated protein kinase dependent apoptosis in androgen independentprostate cancercells C4 and C422. Cancer Res, 2001, 61 (20) : 7408-74012.
[48] Heinrich PC, Behrmann I , Haan S , et al. Principles ofinterleukin ( IL) -6 type cytokine signalling and its regulation. Biochem J, 2003, 374 (Pt 1): 1-20.
[49] Sadar MD, Gleave ME. Ligand independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res, 2000, 60(20) : 5825-5831.
[50]Ye J , Wang S , Barger M , et al . Activation of androgen response element by cadmium: a potential mechanism for acarcinogenic effect of cadmium in the prostate. J Environ Pathol Toxicol Oncol, 2000 , 19 (3) : 275-280.
[51] Yeh S, Sampson ER , Lee DK, et al . Functional analysis of androgen receptor N terminal and ligand binding domain interacting coregulators in prostate cancer. J Formos MedAssoc , 2000, 99 (12) : 885-894.
[52]Ueda T , Mawji NR , Bruchovsky N , et al . Ligand independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostatecancer cells. J Biol Chem, 2002 , 277 ( 41) : 38087-38094.
[53] Lee DK, Duan HO, Chang C , et al . From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH (2) 2terminal associated coactivator. J Biol Chem , 2000 , 275 (13) : 9308-9313.
[54] Wang X , Deng H , Basu I , et al . Induction of androgen receptor dependent apoptosis in prostate cancer cells by the retinoblastoma protein. Cancer Res, 2004 , 64 ( 4) : 1377-1385.
[55] Sharma M, Sun Z. 5′TG3′interacting factor interacts with sin3A and represses AR mediated transcription. MolEndocrinol 2001, 15 (11) : 1918-1928.
[56] Comuzzi B, Lambrinidis L , Rogatsch H. The transcriptional coactivator cAMP response element2binding protein2binding protein is expressed in prostate cancer and enhances androgen2 and anti2androgen2induced androgen receptor function. Am J Pathol, 2003, 162 (1) : 233-241.
[57] Chen CD , Welsbie DS , Tran C , et al . Molecular determinants of resis2tance to antiandrogen therapy [J]. Nat Med, 2004, 10(1) :33.
[58] Gregory CW, Johnson RT , Mohler JL , et al . Androgen receptor stabiliza2tion in recurrent prostate cancer is associated with hypersensitivity to low androgen [J ] . Cancer Res, 2001,61 (7):2892.
[59]Weber MJ, Gioeli D. Ras signaling in prostate cancer progression [J ] . JCell Biochem, 2004,91 (1) :13-24.
[60] Matias PM, Donnor P , Coelho R , et al . Structure evidence for ligand specificity in the binding domain of the human androgen receptor: implications for pathogenicgene mutations. J Biol Chem, 2000 , 275(34): 26164-26171.
[61]Corcoran NM, Costello AJ . Interleukin26: minor player or starring role in the development of hormone2refractory prostate cancer ?BJU Int , 2003 , 91 (6) : 545-553.
[62]Mononen N , Syrjakoski K, Matikainen M , et al . Two percent of Finnish prostate cancer patients have a germline mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res, 2000, 60 (22): 6479-6481.
[63] Gottlieb B, Beitel LK, Lumbroso R, et al. Update of the androgen receptor gene mutations database. Hum Mutat,1999, 14(2): 103-114.
[64]Peterziel H, Culig Z, Stober J, et al. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding Inst J Cancer 1995, 63(4): 544-550.
[65]Ceraline J, Erdmann E, Erbs P, et al. A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer Eur J Endocrino, 2003, 148(1): 99-110.
[66]Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res 1999,59(11): 2511-2515.
[67] Elo JP, Kvist L, Leinonen K, et al. J Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol Clin EndocrinolMetab 1995, 80(12): 3494-3500.
[68]Wang LG, Ossowski L, Ferrari AC. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line Cancer Res 2001, 61(20): 7544-7551.
[69]Nazareth LV, Stnioen DL, Bingman WE, et al. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) Mol Endocrinol1999, 13(12): 2065-2075.
[70] Marcelli M, Ittmann M, Stefania M, et al. Androgen receptor mutations in prostate cancer Cancer Res2000, 60(4): 944-949.
[71]ZhaoXY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 2000, 6(6): 703-706.
[73]Grande M,Carlstrom K,Rozell BL,et al.Tissue concentrations of tissuepolypeptide antigen(TPA) and prostatic specific antigen(PSA) in 42 pa2tients with prostatic carcinoma[J ] . Prostate ,2000 ,45 (4) :299.
[73] Cluetjens CBJM, Steketee K, van Eekelen CCEM, at al . Both androgenreceptor and gllucocorticoid receptor are able to induce prostate - specif2ic antigen expreesion ,but differ in their growth stimulating properties ofLNCaP cell [J ] . Endocrinology ,1997 ,138 (12) :5293.
[74]Devon A, Lawson, Owen N. Witte, et al. Stem cell in prostate cancerinitiation and progression[J ] .Clin. Invest, 2007 ,117(18) :2044.
[75]Collins AT, Berry PA, Hyde C, et al . Prospective identification of tumorigenic prostate cancer stem cells [J ] . Cancer Res , 2005 , 65 (23) :10946-10951.
[76]O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17- hydroxylase/ C (17, 20) - lyase inhibitor abiraterone acetate(CB7630) in patients with prostate cancer [J ] . Br J Cancer ,2004 ,90(12) :2317-2325.
[77]Adam Schayowitz, Gauri Sabnis, Vincent C. O. Njar, et al . Synergisticeffect of a novel antiandrogen, VN/ 124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro[J] . Molecular Cancer Therapeutics, 2008 ,7 (1) :121-132.
[78] Stec A, Mochol J, Kurek L , et al. The influence of different factors on selenium levels in dairy cow herds in the central– eastern region of Poland. Polish Journal of Veterinary Science, 2005,8(3):225-229.
[79]Luoma P. Antioxidants, infections and environmental factors in health and disease in northern Finland. International Journal of cir cumpolar Health, 1998;57(2～3):109-113.
[80]张在香.哺乳动物硒蛋白的研究进展.生理科学进展.1998,29(1):29-31.
[81]Wu QZ, Kuang KX. Effect of long-term Se deficiency on the antioxidant capacities of rat vascular tissue. Biological Trace Element Research, 2004, 98(2):73～84.
[82]赵晶,康世良,王伟.肌注亚硒酸钠后仔猪血硒浓度与抗氧化系统动态变化.动物医学进展,2002,23(6):93～100
[83]Smith A, Madden KB, Yeung KJ, et al. Deficiencies in selenium and/or vitamin E the resistance of mice to Helig–mosomoides polygyrus infections, Journal of Nutrition, 2005, 135(4):830～836.
[84] Albers R, Bol M, Bleumink R et al. Effectes of supplementation with vitamins A, C,and E, selenium, and zinc on immune function in a murine sensitization model. Nutrition, 2003, 19 (11-12):940～946.
[85] Ogunlewe J. Zinc and cadmium concentration - digenous biacks with normal, hypertrophy,and malignant prostate. Cancer, 1989, 63(3) :1388-1391.
[86]高楠,陈维佳.微量元素硒与人类健康最新研究进展.沈阳医学院学报, 2003,5(4):259～264.
[87] Nouarie M, .Pourshams A, Kamangar F, et al. Ecologic study of serum selenium and upper gastrointestinal cancers in Iran [J]. World J Gastroenterology,2004, 10(17): 2544-2546.
[88]Jacobs E T, Jiang R, Alberts D S, et al. Selenium and colorectal adenoma: results of a pooled analysis[J]. J Natl Cancer Inst, 2004, 96(22):1669-1675.
[89] Wei W Q, Abnet C C, Qiao Y L, et al. Prospective study of serum selenium concentrations and esophageal and gastric cardiac cancer, heart disease, stroke, and total death[J]. Am J Clin Nutr, 2004, 79(1):80-85.
[90] Kellen E, Zeegers M, Buntinx F.Selenium is inversely associated with bladder cancer risk:a report from the Belgian case control study on bladder cancer[J].Int J Urol,2006, 13(9):11802-11804.
[91] Thirunavukkarasu C, Babu E, Ebrahim A S, et al. Antioxidant associated chemoprevention by sodium selenite in nitrosodiet hylamine2induced and Phenobarbital promoted hepatocarcinogenesis in rats[J].Cell Biochem Funct, 2004, 22(4):265-271.
[92]刘家国,赵洪进,王小龙,等.富硒麦芽对二乙基亚硝胺所致大鼠肝癌、伴癌综合征及血糖调节相关激素的影响[J].南京农业大学学报,2005,28(4): 90-95.
[93] Liu JG, Zhao HJ, Wang XL, et al. Effect of selenium enriched malt on hepatocarcinogenesis, paraneoplastic syndrome and the hormones regulating blood glucose in rats treated by diet hylnitrosamine, 2006, 78(20):2315-2321.
[94]刘泽,崔文明,韩驰.富硒茶防癌作用实验研究[J].中国职业医学, 2005, 32 (4):22-24.
[95]Rudolf E, Radocha J, Cervinka M, et al. combined effect of sodium selenite and campthotecin on cervical carcinoma cells. Neoplasma,2004, 51(2):127-135.
[96]王敏,朱劲华,马宇翔.含硒紫球藻胞外多糖的制备及对体内外肿瘤细胞生长的影响[J].海洋科学,2006, 30(1):23-27.
[97]Zhao H, Whitfield M L, Xu T, et al. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells[J] . Mol Biol Cell,2004, 15(2): 506-519.
[98]刘艳波,赵丽娟,赵雪俭等.甲基化硒酸对人前列腺癌DU145细胞增殖与凋亡的影响.吉林大学学报(医学版),2008, 34(6):967-910.
[99]轩艳,张宝元,周玲.硒元素对卵巢癌患者化疗的影响[J].国外医学:医学地理分册,2005, 26(2):58-61.
[100] Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients[J].Cochrane Database Syst Rev,2006, 3 19;3:CD005037.
[101] YenJK, ChaSD, ChoCH, et al. Se methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpainin SKOV23 ovarian cancer cells[J].Cancer Lett,2002,182(1):83-92.
[102]Medina D, Thompson H, Ganther H, et al. Se methylselenocysteine:a new compound for chemoprevention of breast cancer[J].Nutr Cancer,2001, 40 (1):12-17.
[103]Jiang C, Wang Z, Ganther H, et al. Caspases as key executors of Methylselenum induced apoptosis(anoikis)ofDU145 prostate cancer cells[J].Cancer Res,2001, 61(7):3062-3070.
[104]Jung U, Zheng X, Yoon SO, et al. Se methylselenocysteine induces apoptosis mediated by reactive oxygen species in HL260 cells[J]. Free Radic Biol Med, 2001, 31(4):479-483.
[105]Ip C, Thompson HJ, Zhu Z, et al. In vitro and in vivo studies of Methylseleninic acid: evidence that amonomethylatedselenium metabolite is critical for cancer chemoprevention [J].Cancer Res, 2000, 60(11):2882-2886.
[106]Dong Y, Soo OL, Zhang HT, et al. Prostate specific antigen expression Is downregulated by selenium through disruption of androgen receptor signaling [J].Cancer Res,2004,64(1):19-22.
[107]Soo OL, Nadiminty N, Xiu XW, et al. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells[J].Cancer Res,2005,65 (8) :3487-3492.
[108]SinhaR, Unni E, Ganther HE, etal. Methylseleninic acid, a potent growth inhibitor of synchronized mouse mammary epithelial tumor cells in vitro [J]. Bio chem. Pharmacol, 2001, 61(3):311-317.
[109] DongY, Zhang H, Hawthorn L, et al. Delineation of the molecular basis for selenium induced growth arrest in human prostate cancer cells by oligonucleotide array [J].Cancer Res,2003,63 (1) :52-59.
[110] Lu Zuo, Jian Li, Yang Yang, et al. Sodium selenite induces apoptosis in acute promyelocytic leukemia derived NB cells by a caspase 3dependent mechanism and a redox pathway different from that of arsenic trioxide [J].Ann Hematol,2004, 83(12):751 -758.
[111] Zhao R, Xiang N, Frederick E, et al. Expression of p53 enhances selenite induced superoxide production and apoptosis in human prostate cancer cells[J]. Cancer Res, 2006, 66 (4):2296-2304.
[112]Zeng H, Mary B A, Joseph PI, et al. The selenium metabolite methylselenol inhibits the migration and invasion potential of ht1080 tumor cells [J]. JNutr, 2006, 136(6):1528 -1532.
[113] Zhu Z, Kimura M, Itokawal Y, et al. Effect of selenium on malignant tumor cells of brain[J]. Biol Trace Elem Res.1995, 49(1):1-7.
[114] Danesi F, Malagut IM, Nunzio M D, et al. Counteraction of adriamycin-lnduced oxidative damage in rat heart by selenium dietary supplementation[J].Agric Food Chem 2006, 54(4): 1203-1208.
[115] Fang Y Z, Yang S, Wu G Y. Free radicals, antioxidants,and nutrition[J]. Nutrition,2002,18(10):872–879.
[116] Al-taie O H, Uceyler N, Eubner U, et al. Expression profiling and genetic alterations of the selenoproteins GI-GPx and Se PP in colorectal carcinogenesis [J]. Nutr Cancer,2004, 48(1):6-14.
[117]Yang JY, Wang ZR. The antitumor effects of selenium compound Na5SeV5O18.3H20 in K562 cell [J].Arch Pharm Res,2006,29(10):859-865.
[118]Wu Y, Zhang H, DongY, et al. Endoplasmic reticulum stress signal mediators are targets of selenium action [J].Cancer Res,2005,65(10) :9073-9079.
[119] KimYS, Jhon DY, Lee KY. Involvement of ROS and JNK 1ink selenite induced apoptosis in Chang liver cells[J]. Exp Mol Med 2004,36(2):157-164.
[120] Jun P, Liu W. The responses of HT22 cells to the blockade of mitochondrial complexes and potential protective effect of selenium supplementation [J]. Int J Biol Sci,2007,3 (5) :335-341.
[121]孙茹,王欣,魏欣冰,等.羟乙葛根素对大鼠局灶性脑缺血再灌注损伤细胞凋亡及p53表达的影响[J].中国生化药物杂志,2004,25 (6):336-338.
[122]Hu H, Jiang C, Schuster T, et al. Inorganic selenium sensitizes prostate cancer cells to TRAIL induced apoptosis through superoxide/p53/Bax mediated activation of mitochondrial pathway [J]. Mol Cancer Ther, 2006,5(7):1873-1882.
[123]裴小娟,苏敏,田东萍.硒-甲基硒代半胱氨酸对人食管癌EC109细胞Ki-67及Bcl-2/Bax蛋白表达的影响[J].汕头大学医学院学报,2004,17(2):65- 67.
[124]张哲文,魏虎来,苏海翔,等.硒酸酯多糖诱导白血病多药耐药细胞凋亡的作用机制[J].中国临床药理学与治疗学,2005;10(5):505-508.
[125]张敬,张军,赵燕,等.硒化合物和维生素E对白血病细胞凋亡及c-Myc基因表达的影响[J].营养学报,2001,23(4):324-326.
[126]Alexander V, Gasparian, YaoY, et al. Selenium compounds inhibit IκB kinase (IKK) and nuclear factorκB (NF-κB) in prostate cancer cells [J]. Mol Cancer Ther, 2002, 10 (1):1079-1087.
[127]DongY,Ganther HE, Stewart C, etal. Identification of molecular targets associated with selenium induced growth inhibition in human breast cancer cells using cDNA microarrays [J].Cancer Res, 2002,62(3):708-714
[128] Zhu Z, Jiang W, Ganther HE, et al. Mechanisms of cell cycle arrest by methylseleninic acid [J].Cancer Res,2002,62(3):152-164.
[129]El, Bayoumy K, Sinha R. Molecular chemoprevention by selenium : age nmic approach [J].Mutat Res Fundam Mol Mech Mutagen,2005, 591(122) :224-236.
[130]Zhao H, Michael L, Whitfield, et al. Diverse effects of methylse Leninic acid on the transcriptional program of human prostate cancer cells [J].Mol Biol Cell, 2004, 2 (15) :5022519.
[131]冯月秋,王束枚,张岫美.乙酰葛根素对血管紧张素Ⅱ致血管内皮细胞凋亡的抑制作用[J].中国生化药物杂志,2007;28(1):11-14.
[132]赵任,郁宝铭,郑民华,等.硒化合物对淋巴细胞杀伤大肠癌细胞过程中Fas/FasL表达的影响[J].中华实验外科杂志,2001;18(1):21-23.
[133]Kim I Y, Stadtman T C. Inhibition of nf-kb dna binding and nitric oxide induction in human t cells and lung adenocarcinoma cells by selenite treatment[J].Proc Natl Acad Sci USA, 199, 94(24): 12904-12907.
[134]Howard E G.Selenium metabolism selenoproteins and mechanisms of cancer prevention complexities with thioredoxin reductase [J].Carcinogenesis, 1999, 20(9):1657-1666.
[135]Kiremidjian-Schumacher L, Roy M.Selenium and immune function [J]. Ernahrungswiss,1998, 37(Suppl1):50-56.
[136]Shi C Y, Chua S C, Lee H P, et al. inhibition of afiatoxinbl-DNA binding and adduct formation by selenium in rats[J].Cancer Lett, 1994, 82(2):203-208.
[137]Erin E B, Nathan R P, Julia L B. The Central Role of Metal Coordination in Selenium Antioxidant Activity[J]. Inorg Chem, 2006, (45): 499-501.
[138]Wilke B C, Viddailhet M, Favier A, et al. Selenium glutathione peroxidsase (GSH-Px) and lipid peroxidation products before and after selenium supplementation[J].Clin Chim Acta, 1992, 207(1-2):137-142. .
[139] Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumor genesis [J]. Cel, 1996, 86 (3): 353-364.
[140] Zetter BR. Angiogenesis and tumor metastasis [J]. Annu Rev Med, 1998, 49(4) : 407-424.
[141]Grunstein J, Roberts WG, Mathieu Costello O, et al. Tumor derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function [J]. Cancer Res,1999, 59 (7) :1592-1598.
[142]Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promote ractivity in stromal cells [J]. Cel , 1998, 94(6): 715-725.
[143] Ferrara N, Carver-Moore K, Chen H, et al. Heterozgous embryonic lethality induced by targeted inactivation of the VEGF gene[J]. Nature, 1996, 380(4): 439-442.
[144] Aonuma M, Saeki Y, Akimoto T, et al . Vascular endothelial growth factor overproduced by tumor cells acts predominantly as a potent angiogenic factor contributing to malignant progression[J]. Int J Exp Pathol, 1999, 80(5): 271-281.
[145] Deroanne CF, Hajitou A, Calberg-Bacq CM, et al. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up regulation of vascular endothelial growth factor expression[J] . Cancer Res, 1997,7(24): 5590-5597.
[146]Eric A, Ian M, Scott M, et al. The selenium and vitamin E cancer prevention trial [J ].Urologic Oncology,2003, 21(2):59-65.
[147] Karam EB, Arunang SD, Telih B, et al. Comparative action of 1 ,4phenyleneb is (methylene) selenocyanate and it s metabolites against 7 , 1-2dimet hylbenz [ a ] anthracene-DNA adduct formation in the rat and cell proliferation in rat mammary tumor cells [J]. Chemico Biological Interactions,2003, 146 (2): 179-190.
[148]Jiang C, Ganther H, Lu JX. Monomethyl selenium specific inhibition of MMP2 and VEGF expression:implications for angiogenic switch regulation [J]. Mol Carcinog, 2000, 29 (4):236-250.
[149]Clark LC, Combs GF, Turnbull BW, et al. Effect s of selenium supplementation for cancer prevention in patient s with carcinoma of the skin: a randomized controlled trial [J]. JA-MA, 1996, 276(24):1957-1963.
[150]Guidi A J, Schnitt SJ, Fischer L, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patient s with ductal carcinoma in situ of the breast [J]. Cancer, 1997, 80(10) :1945-1953.
[151]Folkman J. The role of angiogenesis in tumor growth[J]. Semin Cancer Biol,1992, 3(2): 65-71.
[152]Wang Z, Jiang C, Ganther H, et al. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3 KA KT, ERK, JNK and p38MARK signaling [J]. Cancer Res, 2001, 61(19): 7171-7178.
[153] Stewart MS, Spallholz JE, Neldner KH, et al. Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis[J]. Free Radic Bio Med, 1999, 26(1-2): 42-48.
[154]王坤,迟永春,王君,等.微量元素硒对HL-60细胞凋亡的诱导及bcl-2/bax基因的表达调控[J].中日友好医院学报,2001;15(3): 150-155.
[155]张敬,张军,赵燕,等.硒和维生E对白血病细胞凋亡及c-Myc基因表达的影响[J].营养学报,2001;23(4):324-326
[156]Caffrey PB, Frenkel GD. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo[J].Cancer Chemother Pharmacol,2000 ,(46): 74-78.
[157]俸家富.硒蛋白和硒的抗癌机理[J].微量元素与健康研究,2001;18(1): 70 -72.
[158]Cindy D, Eric OV, John WF. Dietary selenium and arsenic affect DNA ethylation in vitro in CACO cells and in vivo rat liver and colon[J]. ASNS, 2000, 130(12): 2903-2909.
[159]Zhang GX, Zhao ZQ, Wang HD. Enhancement of osteopontin expression in HepG-2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway [J].World J Gastroenterol, 2004, (10): 205-208.
[160] Klein EA. Selenium-epidemiology and basic science [J]. J Urol, 2004, 171(2pt2):50-53.
[161]Ashughyan VR, Marihart S, Djavan B. Chemopreventive Trials in Urologic Cancer [J]. Reviews in urology 2006, 8(1):8-13.
[162] Brinkman M, Reulen RC, Kellen E,et al. Are men with low selenium levels at increased risk of prostate cancer [J] Eur J Cancer, 2006, 42(15), 2463–2471.
[163]Vogt TM, Ziegler RG, Graubard BI, et al. Serum Se and risk of prostate cancer in U.S. blacks and whites [J].Int J Cancer, 2003,103(5):664-670.
[164]Dufield-Lillico AJ, Dalkin BI, Reid ME, et al. Se supplementation, baseline plasma Se status, and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer study group[J]. Br J Urol Int, 2003,91(7):608-612.
[165]Van den Brandt PA, Zeegers MP, Bode P, et al. Toenail selenium levels and the subsequent risk of prostate cancer:a prospective cohort study[J] .Cancer Epidemiol Biomarkers Prev ,2003,12(9):866-871.
[166] Zhao H , Whitfield ML, Xu T, et al. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells[J]. Mol Biol Cell, 2004,15(2):506- 519.
[167]Cho SD, Jiang C, Malewicz B, et al. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription[J]. Mol Cancer Ther , 2004, 3(5): 605–611.
[168]Lee SO, Chun JY, Nadiminty N, et al. Monomethylated Selenium InhibitsGrowth of LNCaP Human Prostate Cancer Xenograft Accompanied by a Decrease in the Expression of Androgen Receptor and Prostate-Specific Antigen(PSA)[J]. Prostate,2006,66(4):1070- 1075.
[169]Waters DJ, Shen S, Cooley DM,et al. Effects of dietary Se supplementation on DNA damage and apoptosis in canine prostate[J]. J Natl Cancer Inst,2003,95(3):237-241.
[170]Gianduzzo TR, Holmes EG, Tinggi U, et al. Prostatic and peripheral blood selenium levels after oral supplementation [J]. J Urol,2003, 170(3): 870-873.
[171]Bhamre S, Whitin JC, Cohen HJ. Selenomethionine does not affect PSA secretion independent of its effect on LNCaP growth [J]. Prostate, 2003,54(4): 315-321.
[172]Rebsch CM, Penna FJ, Copeland PR. Selenoprotein expression is regulated at multiple levels in prostate cells [J]. Cell Res. 2006, 16(12): 940-948.
[173] Pinto JT, Sinha R, Papp K, et al. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells[J]. IntJ Cancer. 2007, 24(7):1410-1417.
[174] Zu K, Ip C. Synergy between selenium and Vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells[J]. Cancer Res, 2003,63(20): 6988-6995.
[175]应俊,姚德鸿,任晓敏.前列腺癌去势术前后雄性激素变化的研究[J].中华男科学, 2003,6(3):191～196.
[176]夏同礼.前列腺癌的基础与临床[M].北京:科学出版社,2000,227～238.
[177] InWalsh PC , Retik A B , Vaughan E D, of the prostate and seminal vesicles [A].et al.Campbell’s Urology[M]. 7thed, New York: Philadephia , Saunder, 1998, 1379～1428.
[178]Connell JM. 5-Alpha reductase in prostate disease[A].Kirby R, Connell J M, Fitzpatrick J,et al. Textbook of prostatic hyperplasia[M].London: ISIS Medical Media,1996, 85～90.
[179]Arner ES, Holmgren A. The thioredoxin system in cancer [J]. Semin. Cancer Biol, 2006, 16(6):420-426.
[180]Grubb RL 3rd, Black A, Izmirlian G,Serum Prostate-Specific AntigenHemodilution Among Obese Men Undergoing Screening in the Prostate, Lung, Colorectal, and Ovarian [181]Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009, 18(3):748-751.
[181]Dudkin VY, Miller JS, Dudkina ASToward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. J Am Chem Soc. 2008, 130(41):13598-13607.
[182] Jiang H, Semenza GL, Bauer C, et al. Hypoxia-inducible factor-1 level vary exponentially over a physiologically relevant range of O2 tense[J]. Am J Physiol, 1996, 271(4 pt1):1172-1180.
[183]Semenza GL. Regulation of mammalian O2 hemeostasis by hypoxia-inducible factor 1 [J]. Annu Rev Cell Dev Biol, 1999,15(8): 551-578.
[184] Carmeliet P, Dor Y, herbert JM,et al. Role of HIF-1 alpha in hypoxia-mediated apopotosis cell prolifewration and tumor angiogenesis[J]. Nature,1998, 394(6692) :485-499.
[185] Zhong H, Demarzo AM, Laughner E,et al. Overexpression of hypoxia-inducible factor 1 alpha in comom human cancers and their metastases[J]. Cancer Res, 1999, 599(22): 5830-5835.
[186]Ling MT, Wang X, Lee DT, et al. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Carcinogenesis, 2004, 25(4): 517-525.
[187]Taplin ME, Ho SM. Clinical review 134: The endocrinology of prostate cancer. J Clin Endocrinol Metab, 2001, 86(8): 3467-3477.
[188]Twillie DA, Eisenberger MA, Carducci MA, et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 1995, 45(3): 542-549.
[189]Assikis VJ, Do KA, Wen S, Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res. 2004, 10(20):6770-8.
[190]Huang HF, Murphy TF, Shu P, Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer. 2005, 4(1):25-38.
[191]Dong Y, Zhang H, Hawthorne L, et al. Delineation of the molecular basis for Se-induced growth arrest in human prostate cancer cells by oligonucleotide array[J]. Cancer Res, 2003,63:52-59.
[192]Zhang H, Wu Y, Malewicz B, et al.Augmented suppression of androgen receptor signaling by a combination of alpha-tocopheryl succinate and methylseleninic acid, 2006, 7(12):2942-2948.
[193]Lee SO, Chun JY, Nadiminty N,et al. Monomethylated Selenium Inhibits Growth of LNCaP Human Prostate Cancer Xenograft Accompanied by a Decrease in the Expression of Androgen Receptor and Prostate-Specific Antigen(PSA)[J]. Prostate, 2006,66(4):1070- 1075.
[2] Crook NE, Clem RJ, Miller LK, et al. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif [J] . J Virol 1993, 67(4): 2168-2174.
[3] Nachmias B, Ashhab Y, Ben-Yehuda D, et al. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer[J]. Semin Cancer Biol 2004,14(4):231-243.
[4] Koike H, Sekine Y, Kamiya M, et al. Gene expression of Survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology. 2008, 72(6):1229-33.
[5] Jiang X, Wilford C, Duensing S, et al. Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells [J]. J Cell Biochem, 2001,83(2):342-354.
[6] Li F, Abmrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by Survivin [J]. Nature,1998,369 (6711): 580-584.
[7] Skoufias D A, Mollinari C Lacroix F B, et al. Human Survivin of apoptosis and mitotic spindle is a kinetochore-associated passenger protein [J]. J Cell Biol. 2000,151(7):1575-1582.
[8] Jiang X, Wilford C, Duensing S, et al. Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells [J]. J Cell Biochem,2001,83(2):342-354.
[9] Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with Survivin function [J].Nature Cell Biol,1999,1(8):461-466.
[10] Skoufias D A, Mollinari C Lacroix F B, et al. Human Survivin of apoptosis and mitotic spindle is a kinetochore-associated passenger protein [J]. J Cell Biol. 2000,151(7):1575-1582.
[11] Wheatley SP, Carvalho A, Vagnarelli P, et al. INCENP is required for proper targeting of Survivin to the centromeres and the anaphases pindle during mitosis[J]. Curr Biol, 2001,ll(11): 886-890.
[12] Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immuno- chemicallydistinct subcellular pools and is involved in spindle microtubule function[J].J Cell Sci. 2002,115(3):575-585.
[13] Lehner R, Bobak J, Kim NW, et al . Localization of telomerasehtert protein and Survivin in placenta: relation to placental development and hydatidiform mole[J]. Obstet Gynecol. 2001,97(6): 965-970.
[14] Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by Survivin predicts shorter survival rates in colorectal cancer[J]. Cancer Res. 1998, 58 (22):5071-5074.
[15] Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes [J]. Nat Genet. 1999,23 (4):387-388.
[16]张洪珍,段昕波,刘国魁,等.食管癌Survivin、血管内皮生长因子蛋白表达及临床意义[J].河北医科大学学报.2007,28(1):5-8. [ 17 ] Xu J H, Huang HZ, Pan CB, et al . Role of Survivin gene on the apoptosis of Tca8113 cells induced by cisplatin [J]. Hua Xi Kou Qiang Yi Xue ZaZhi.2007, 25 (2):173-176
[18] Zwicker J, Lucibello Fc, Wolfraim LA, et al. Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes based on a common mechanism of transcriptional repression [J]. EMBO J, 1995, 14(18): 4514-4522.
[19] Chiou SK, Jones MK, Tarnawski AS. Survivin—an antiapoptosis protei: its biological roles and implications for cancer and beyond [J]. Med Sci Monit 2003 , 9(4):125-129.
[20] Papapetropoulos A, Fulton D, Mahboubi K, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/Survivin pathway [J]. J Biol Chem. 2000, 275(13): 9102-9105.
[21] Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins Survivin and XIAP by VEGF in vascular endothelial cells [J]. Biochem Biophys Res Commun. 1999, 264 (3):781- 788.
[22] Kirkiles-Smith NC, Mahboubi K, Plescia J, et al. IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of Survivin expression[J]. J Immunol. 2004, 172(3):1391- 1396.
[23] Mahboubi K, Li F, Plescia J, et al. Interleukin-11 up- regulates Survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway [J]. Lab Invest. 2001, 81(3):327-334.
[24] Altznauer F, Martinelli S, Yousefi S, et al. Inflammation- associated cell cycle-independent block of apoptosis by Survivin in terminally differentiated neutrophils[J]. J Exp Med. 2004, 199(10):1343-1354.
[25] Das A, Tan WL, Teo J, et al. Expression of Survivin in primary glioblastomas.J Cancer Res Clin Oncol. 2002, 128 (6):302-306.
[26] Mirza A, McGuirk M, Hockenberry TN, et al. Human Survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway[J]. Oncogene, 2002, 21(17): 2613-2622.
[27] Hoffman WH, Biade S, Zilfou J T, et al. Transcriptional repression of the anti-apoptotic Survivin gene by wild type p53 [J]. J Bio1 Chem.2002, 277(5):3247-3257.
[28] Chao JI, Kuo PC, Hsu TS. Down-regulation of Survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells[J]. J Biol Chem, 2004 ,279(19): 20267-20276.
[29] Faqing T, Zhi H, Liqun Y, et al . Epstein-Barr virus LMP1 initiates cell proliferation and apoptosis inhibition via regulating expression of Survivin in nasopharyngeal carcinoma [J]. Exp Oncol, 2005,27(2):96-101.
[30] Islam A, Kageyama H, Hashizume K, et al. Role of Survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, Survivin-beta/2B[J]. Med Pediatr Oncol 2000,35(6):550–553.
[31] Hatori M, Sakamoto H, Satoh K, et al. DNA demethylase (dMTase) is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and Survivin genes exonl[J]. Cancer Lett, 2001,169(2):155-164.
[32]MillerLK. An exegesis of IAPS: salvationandsurprises from BIR motifs[J].Trends.Cell Biol,1999, 9(8):323-328.
[33] SunC, CaiM, Gunasekera AH, et al. NMR structure and mutagenesis of the inhibitor of apoptosis ptotein XIAP[J].Nature,1999, 401(6755):818-821.
[34] TammI, WangY, Sausville E, et al. IAP family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs [J]. CancerRes, 1998,58(23):5315-5320.
[35] Riedl SJ, Renatus M, Schwarzenbacher R, et al. Structural basis for the inhibitionof caspase3 byXIAP[J].Cell,2001,104(5):791-800.
[36] ShiY. Survivin structure: crystal unclear [J].Nat Struct Biol,2000;7(8):620 -623
[37] O’Connor DS, Grossman D, Plescia J, et al. Regulation of Apoptosis at cell division by p34cdc2 phosphorylation of Survivin[J]. Proc Natl Acad Sci USA. 2000,97(24):13103-13107.
[38] Du C, Fang M, Li L, et al. Smac mitochondrial protein that promotes cytochromec 2 dependent caspase activation by eliminating IAP inhibition [J]. Cell, 2000,102(1):33-42.
[39] Abrams J. An emerging blueprint for apoptosis in drosophila [J]. Trends Cell Biol. 1999,9 (11):435-40.
[40] Suzuki A, Ito T, KowanoH, et al. Survivin initiates procaspase3 Pp21 complex formation as a result of interaction withCdk4 to resist Fas mediated cell death [J]. Onco gene, 2000, 19(10):1346-1353.
[41] Fortugno P , Wall NR , Giodini A , et al . Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function[J ] .J Cell Sci,2002,115 (3):575—585.
[42] Chen J. Wu W Tahir SK, et al. Down-regulation of Survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth [J]. Neoplasia, 2000, 2(3):235-241.
[43] Suzuki A, Hayashida M, Ito T, et al. Survivin in initiates cell cycle entry by the competitive interaction with Cdk4/pl6(INK4a) and Cdk2/cyclin E complex activation[J]. Oncogene, 2000,19(29):3225-3234.
[44] Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death [J]. Oncogene, 2000, 19(10):1346–1353.
[45] O’Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of Survivin[J]. Proc Natl Acad Sci USA, 2000,97(24): 13103–13107.
[46] O’Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by Survivin expression in endothelial cells [J]. Am J Pathol, 2000,156:393–398,
[47] Mesri M, Wall NR ,Li J, et al . Cancer gene therapy using a Survivin mutant adenovirus [J]. J Clin Invest ,2001, 108(7): 981-990.
[48] Beierle EA, Nagaram A, Dai W, et al. VEGF-mediated Survivin expression in neuroblastoma cells[J]. J Surg Res. 2005,127(1):21-28.
[49] Beardsmore D M , Verbeke C S , Davies C LApoptotic and proliferative indexes in esophageal cancer : predictors of response to neoadjuvant therapy apoptosis and proliferation in esophageal cancer[J]. J Gastrointest Surg, 2003,7(1) :77–87.
[50] Zhang XY, Zhong L H, Hu K, et al . Expression of Survivin and it’s correlation with P53 in non small cell lung cancer [J]. Med J Wuhan University,2004,25 (3) :271–274.
[51] Meng H , Lu C , Mabuchi H , et al . Prognostic significance and different properties of Survivin splicing variants in gastric cancer [J].Cance Lett, 2004,216(2):147–155.
[52] Nakamura M, Tsuji N, Asanuma K, et al. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients [J]. Cancer Sci, 2004, 95(1):44 -51.
[53] Zhang M, Latham DE, Delaney MA, et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer [J]. Oncogene,2005,24(15): 2474–2482.
[54] Zhang M, Mukherjee N, Bermudez RS, et al. Adenovirus- mediated inhibition of Survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo [J]. Prostate, 2005, 64 (3):293–302.
[55] Li F. Role of Survivin in cancer chemoprevention [J]. Assay Des-Simply Sci,2005, 1(1):2–6.
[56] Li F, Ling X, Huang H, et al . Differential regulation of Survivin expression and apoptosis by vitamin D(3) compounds in two isogenic MCF-7 breast cancer cell sublines[J]. Oncogene,2005,24(8):1385–1395.
[57]Takamizawa S, Scott D, Wen J,et al. The Survivin: fas ratio in pediatric renal tumors. JPediat r Surg, 2001, 36 (1) : 37- 42.
[58] Xing N, Qian J, Bostwick D, etal. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein Survivin.Prostate, 2001,48 (1) :7- 15.
[59]Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol [J]. Cancer Res, 2004, 64 (1):337-346.
[60] Kishi H, Igawa M,Kikuno N. Expression of the Survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity andapoptosis[J]. Ology, 2004, 171(5):1855-1860.
[61] Shariat SF, Lotan Y, Saboorian H,et al.Survivin expression is associated with features of biologically aggressive prostate carcinoma[J]. Cancer, 2004, 100(4): 751-757.
[62] Fromont G, Chene L, Vidaud M, et al. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR[J]. Int J Cancer, 2005,114 (2):174–181.
[63] Kaur P, Kallakury BS, Sheehan CE, et al. Survivin and Bcl-2 expression in prostatic adenocarcinomas[J]. Arch Pathol Lab Med,2004,128(1): 39-43.
[64]高吴阳,胡传义,易慕华. Survivin蛋白在前列腺癌中的表达及其与肿瘤细胞凋亡的关系[J].中华男科学, 2004,10(1): 12-14.
[65]张向阳,曾强,齐范. Survivin蛋白在前列腺癌中的表达及其意义[J].中国现代医学杂志,2006,16(7):1060-1062.
[66]夏雪雁,李连宏,李先承.凋亡相关基因Survivin蛋白在前列腺癌组织中的表达及临床意义[J].大连医科大学学报,2006,28(4): 288-289
[67] Shapior GI. Preclinical and clinical development of t hecyclindependent kinase inhibitor flavopiridol [J] . Clin CancerRes, 2004 ,10 (12 Pt 2) :4270-4275. [ 68] Fulda S ,Debatin KM. Sensitization for tumor necrosis factor related apoptosis inducing ligand induced apoptosis by the chemopreventive agent resverat rol [ J ] . Cancer Res, 2004, 64(1):337-346.
[69]辛晓燕,袁鹏,黄艳红,等.染料木黄酮和顺铂对耐药卵巢癌细胞SKOV23中Survivin表达的影响[J].肿瘤,2007,27(1):13-15.
[70] Tu SP, Jiang XH, Lin MC, et al. Suppression of Survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer [J]. Cancer Res, 2003,63(22) :7724 -7732.
[71] Hague A, Eveson JW, MacFarlane M , et al . Caspase3 expression is reduced, in the absence of cleavage, in terminally differentiated normal oral epithelium but is increased in oral squamous cell carcinomas and correlates with tumour stage[J ] . J Pathol 2004, 204(2) :175-182
[72] Shen C, Duck A, Polat B, et al. Triplex forming cligodeoxy nucleotides targeting Survivin inhibitor proliferation and induce apoptosis of human lung carcinoma cells [J ] . Cancer Gene Ther, 2003,10(5) :403-410.
[73] Khanna N, Sen S, Sharma H, et al. S29 ribosomal protein induces apoptosis in H520 cells and sensitizes the mitochemotherapy [J ]. Biochem Biophys Res Commun, 2003,304(1):26-35.
[74] Fuessel S, Herrmann J, Ning S, et al. Chemosesitization of bladder cancer cells by Survivin2directed antisense oligodeoxynucleotides and siRAN [J].Cancer Lett ,2006,232(2) :243-254.
[75] Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity [J]. Anti-Cancer Drugs, 2004,15(5): 411-419.
[76] Gunawardena K, Camphbell LD, Meikle AW. Combination therapy with vitamins C plus E inhibits Survivin and human prostate cancer cell growth [J]. Prostate, 2004,59 (3) :319 -327.
[77] Griffith TS, Kemp TJ. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis [J]. Cancer Chemotherapy & Pharmacology, 2003,52(3): 175- 184.
[78]刘艳波,赵丽娟,赵丽晶等,Survivin-SiRNA对前列腺癌细胞PC-3M增殖的抑制作用.中国病理生理杂志,2008;24(10):1873-1876.
[79] Muenchen HJ, Poncza PJ, Pienta KJ. Different docetaxel- induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC -3[J]. Urology,2001 ,57(2) :366-370.
[80] Kalvakolanu DV. The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression [J]. Cytokine Growth Factor Rev, 2004, 15 (223):169-194.
[81] Chidambaramn V, Angell J E, Ling W, et al. Chromosomal localization of human GRIM-19, a novel IFN beta and retinoic acid activated regulator of cell death [J]. J Interferon Cytokine Res, 2000, 20 (7): 661-665.
[82] Angell JE, Lindner DJ, Shapiro PS, et al. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem, 2000, 275(43): 33416–33426.
[83] Hu J, Angell J E, Zhang J, et al. Characterization of monoclonal antibodies against GRIM-19, a novel IFN beta and retinoic acid activated regulator of cell death [J]. J Interferon Cytokine Res, 2002, 22 (10):1017-1026. [84 ] Huang G, Lu H, Hao A, et al. GRIM-19, a cell death regulatory protein, isessential for assembly and function of mitochondrial complex I[J]1Mol Cell Biol, 2004, 24 (19): 8447-8456. .
[85] Lufei C, Ma J, Huang G, et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction [J].EMBO J, 2003, 22 (6) : 1325-1335.
[86] Zhang X, Huang Q, Yang Z, et al. GW112, a novel anti-apoptotic protein that promotes tumor growth [J]. Cancer Res, 2004, 64 (7): 2474-2481.
[87] Kalakonda S, Nallar S C, Gong P, et al. Tumor suppressive protein gene associated with retinoid interferon induced mortality (GR IM) -19 inhibits src induced oncogenic transformation at multiple levels[J]. Am J Pathol, 2007, 171 (4):1352-1368.
[88] Kalakonda S, Nallar S C, L Indner D J, et al. Tumor suppressive activity of the cell death activator GRIM-19 on a constitutively active signal transducer and activator of transcription [J]. Cancer Res, 2007, 67 (13): 6212-6220.
[89] Zhang J, Yang J, Roy S K, et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription [J]. Proc Natl Acad Sci USA, 2003,100 (16): 9342-9347.
[90] Ma X, Kalakond A S, Srinivasula SM, et al. GRIM-19 associates with the serine protease HtrA2 for promoting cell death[J].Oncogene,2007, 26 (33): 4842-4849
[91] Rozan L M, Eldeiry W S. Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target [J].Cancer Biol Ther, 2006, 5(9) :1228-1235.
[92] Chen Y, Yuen W H, Fu J, et al. The mitochondrial respiratory chain controls intracellular calcium signaling and NFAT activity essential for heart formation in Xenopus laevi [J]. Mol Cell Biol, 2007, 27 (18) : 6420-6432.
[93] Huang G, Chen Y, Lu H, et al. Coup ling mitochondrial respiratory chain to cell death: an essential role of mitochondrial complexI in the interferon beta and retinoic acid induced cancer cell death [J]. Cell Death Differ,2007, 14 (2): 327-337.
[94] Barnich N, Hisamatsu T, Aguirre J E, et al. GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of antibacterial function in intestinal epithelial cells[J]. J Biol Chem, 2005, 280 (19): 19021-19026.
[95] Seo T, Lee D, Shim YS, et al. Viral interferon regulatory factor of Kaposi’s sarcoma associated herpes virus interacts with a cell death regulator, GRIM-19, and inhibits interferon/retinoic acid induced cell death[J]. J Virol, 2002, 76 (17): 8797-8807.
[96] Reevesm B, Daviesa A, Mcsharryb P, et al. Complex I binding by a virally encoded RNA regulates mitochondria induced cell death [J]. Science, 2007, 316 (5829):1345-1348
[97] Ling Z, Lifang G, Yang L, et al. Effects of Plasmid-Based Stat3-Specific Short Hairpin RNA and GRIM-19 on PC-3M Tumor Cell Growth Clin Cancer Res 2008, 14(2):559-568
[98] Papa F, Delia M, Trentadue R, et al. Differential effects of all trans retinoic acid on the growth of human keratinocytes and mouth carcinoma epidermoid cultures involvement of GRIM-19 and complex I of the respiratory chain [J]. Int J Immunopathol Pharmacol, 2007,20 (4): 719-729.
[99] Gong LB, Luo X L, Liu SY, et al. Correlations of GRIM-19 and its target gene product STAT3 to malignancy of human colorectal carcinoma [J]. Ai Zheng, 2007, 26(7): 683-687.
[100] Zhang X, Choem S, Lee JE, et al. GRIM-19 expression and its correlation with clinical outcomes of an induction chemotherapy for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN ) [J]. J Clin Oncol, 2005, 23(16s): 55191
[101] Montini E, Cesana D, SchmidtM, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vectorintegration [J]. Nature Biotechnol, 2006, 24 (6): 687-696.
[102] Blesch A. Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer [J]. Methods, 2004, 33 (2): 164-172.
[103] Taulli R, Accornero P, Follenzi A, et al. RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met -mediated tumor genesis [J]. Cancer Gene Ther, 2005, 12 (5) : 456-463.
[104] Bastone P, Romen F, LiuW, et al. Construction and characterization of effivcient, stable, and safe replication - deficient foamy virus vector [J]. Gene ther, 2007,14 (7): 613～620.
[105] Yant SR, Ehrhardt A, Mikkelsen JG, et al. Transposition from a gutless adeno -transposon vector stabilizes transgene expression in vivo [J]. Nature Biotechnol, 2002, 20 (10): 999-1005
[106] GoncalvesM A, van derVelde I, Knaan - Shanzer S, et al. Stable transduction of large DNA by high - capacity adeno associated virus / adenovirus hybrid vectors [J]. Virol, 2004, 321(2): 287-296.
[107] Vasileva A, Linden RM, Jessberger R. Homologous recombination is required for AAV - mediated gene targeting [ J ]. Nucleic Acids Res, 2006, 34 (11): 3345- 3360.
[108] Lai Y, Yue Y, Liu M, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors [J]. NatBiotechnol, 2005,23(11): 1435-1439.
[109] Guerra S, Lopez - Fernandez LA, Pascual - Montano A, et al. Host response to the attenuated poxvirus vector NYVAC: up regulation of apoptotic genes and NF-kappaB -responsive genes in infected HeLa cells[ J ]. J Virol, 2006, 80 (2): 985-998.
[110]Adusumilli PS, StilesBM, ChanMK, et al. Imaging and therapy of malignant pleural mesothelioma using replication– competent herpes simplex viruses [J]. J Gene Med, 2006, 8 (5): 603 -615.
[111]Shah K, Breakefield XO. HSV amplication vectors for cancer therapy [J]. Current Gen Thera,2006, 6 (3): 361-370.
[112] Timmerman JM, Singh G, Hermanson G, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B - cell lymphoma [J]. Cancer Res, 2002, 62 (20):584-552.
[113]Kim KS, Park YS. Antitumor effects of angiostatin K1-3 and endostatin genes coadministered by hytrodynamics-based transfection method[J]. Onco Res, 2005,15: 343～350.
[114]Serikawa T, Kikuchi A, Sugaya S, et al. In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy [J]. J Controlled Release, 2006, 113(3):255-260.
[115]Li WJ, Szoka FC. Lipid-based nanoparticles for nucleic acid delivery [J]. Pharmaceu res, 2007, 24 (3): 438-449.
[116] Chen J, Tian B, Yin X, et al. Preparation, characterization and transfection efficiency of cationic PEGylated PLA nanoparticles as gene delivery systems [J].J Biotechnol, 2007, 2(8):1166-1175.
[117]Kneuer C, Ehrhardt C, Bakowsky H, et al. The influence of physicochemical parameters on the efficacy of non - viral DNA transfection comp lexes: a comparative study [ J ]. J Nanosci Nanotechnol, 2006, 6 (9-10): 2776-2782.
[118]Liu G, LiD, PasumarthyMK, et al. Nanoparticles of compacted DNA transfect postmitotic cells [J]. J Biol Chem, 2003, 278(35): 32578-32586.
[119]Corsi K, Chellat F, Yahia L, et al. Mesenchymal stem cells,MG63 and HEK293 transfection using chitosan - DNA nanoparticles [J]. Biomaterials,2003, 24 (7):1255-1264.
[120]Ito A, Matsuoka F, Honda H, et al. Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma [ J ]. Cancer Immunol Immunother, 2004,53(1): 26-32.
[121]Iwasaki Y, Ueda M, Yamada T, et al. Gene therapy of liver tumors with human liver-specific nanoparticles [J]. Cancer Gene Ther, 2007,14 (1):74-81.
[122]Schatzlein A G. Non viral vectors in cancer gene therapy: principles and progress [J]. Anticancer Drugs, 2001, 12 (4) : 275-304.
[123] Gupta K, Zhang J. Angiogenesis: a curse or cure [J]. Postgrad Med J, 2005, 81 (954): 236-242.
[124]Nuyts S. Clostridium spores for tumor specific drug delivery [J].Anticancer Drugs, 2002, 13 (2):115-125.
[125]Liu S C, Minton N P, Giaccia A J, et al. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia necrosis[J]. Gene Therapy,2002, 9( 4):291-296.
[126] Yazawa K, Fuj IM , Amano J, et al. Bifidobacterium longum as a delivery system for cancer gene therapy:Selective localization and growth in hypoxic tumors [J]. Cancer Gene Therapy, 2000, 7(2):269-274.
[127]Yazawa K, Fujimor IM, Nakamura T, et al. Bifidobacteriumlongum as a delivery system for gene therapy of chemically induced rat mammary tumors[J]. Breast Cancer Res Treat, 2001, 66( 2):165-170.
[128]Vaupel PW. Oxygenation of solid tumors in drug resistance in oncology [P]. In: Teicher BA, ed. New York: Marcel Dekker, 1993: 532
[129]徐根兴.转人实体瘤内皮抑制因子( Endostatin)基因双歧杆菌的方法[J].发明专利公报,1999,15(20):20.
[130]Nakamura T, Sasaki T, Fujimor IM, et al. Cloned cytosine deaminase gene expression of Bifidobacterium longum and app lication to enzyme /prodrug therapy of hypoxic solid tumors[J]. Biosci Biotechnol Biochem, 2002, 66(11):2362-2366.
[131]Li XI, Fu GF, Fan YR, et al. Bifidobacterium adoles centis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth[J]. Cancer Gene Therapy, 2003,10(2):105-111.
[132]Kochi SK, Killeen KP, Pyan US, et al. Advance in the development of bacterial vector technology. Expert Rev Vaccine,2003,2(1):3d1-43.
[133]Figueroa-Bossi N, Uzzau S, Maloriol D, et al. Variable assortment of pathogenic determinants in Salmonella. Mol Microbiol, 2001, 39(2): 260-271.
[134]Platt J, Sodi S, Kelley M, et al. Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur J cancer, 2000, 36(18): 2397-2402
[135]Sznol M, Lin SL, Bermudes D, et al. Use of preferentially replicating bacteria for the treatment of cancer. J Clin invest, 2000, 105(8): 1027-1030.
[136]Ling Z, Lifang G, Lijuan Z, et al. Intratumoral Delivery and Suppression of Prostate Tumor Growth by Attenuated Salmonella enterica serovar typhi Carrying Plasmid-Based Small Interfering RNAs. Cancer Res. 2007,67(12):5859-5864.
[137]邵月婷,徐德启,刘亚男等.减毒沙门氏菌靶向携带共表达质粒p53/siRNA- Survivin抗前列腺癌的体内研究.中国肿瘤临床.2008,35(9): 527-529.
[138]Rubanyi GM. The future of human gene therapy [J]. Mol AspectsMed, 2001, 22 (3):113-142.
[139]Hirayama K, Rafter J. The role Probiotic bacteria in cancer prevention [J]. Microbes Infect, 2000, 2 (6): 681-686.
[140]Roller M, Pietro FA, Cadern IG, et al. Intestinal immunity of rats with colon cancer is modulated by oligofructose enrichedinulin combined with Lactobacillus rham nosus and B if idobacterium lactis[J]. Br J Nutr, 2004,92(6):931-938.
[141]Singh J, Rivenson A, Tomita M, et al. B if idobacterium longum,a lactic acid producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis [J].Carcinogenesis, 1997,18 (4): 833-841
[142] Jemal A, Thomas A, Murray T, et al. Cancer statistics 2002[J]. CA Cancer J Clin, 2002, 52(3): 181-182.
[143]Kuwahara M, Tochigi T, Kawamura S, et al. Mass screening for prostate cancer: a comparative study in Natori,Japan and Changchun,China[J]. Urology, 2003, 61(1): 137-141.
[144]张灵,计国义,李晓萌,等.前列腺癌集团检诊对临床前列腺癌诊断的影响[J].中华泌尿外科杂志, 2004,25(2):103-105.
[145] Rosa J, Canovas P, Islam A, et al. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle [J]. Mol Biol Cell, 2006, 17:1483–1493.
[146] Arvilommi H.selenium and immune functions in humans infect [J]. Immun, 1983, 41(1):185-189.
[147] Mantovani G, Maccio A, Madeddu C,et al. Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity[J]. J Exp Ther Oncol. 2004,4(1): 69-78.
[148]Fangusarol JR, Jiang Y, Caldas H, et al. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome[J]. British Journal of Cancer, 2005, 92(1): 359-365.
[149]Zhang L, Gao L, Li Y, Lin G, et al. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin Cancer Res. 2008, 14(2):559-568.
[150] Scheper MA, Nikitakis NG, Sauk JJ. Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.
[151]Theys J, Barbe S, Landuyt W, et al. Tumor-specific gene delivery using genetically engineered bacteria. Curr Gene Ther, 2003, 3(3): 207-221.
[152] Guo CC, Ding J, Pan BR, et al. Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhi as carrier. World J Gastroenterol, 2003, 9(6): 1191-1195.
[153]Forbes NS, Munn LL, Fukumura D, et al. Sparse initial entrapment of systemically injected Salmonella typhi leads to heterogeneous accumulation within tumors. Cancer Res, 2003, 63(17): 5188–5193.
[154] Invernizzi R, Travaglino E, Benatti C, et al. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia [J]. Eur J Haematol, 2006,76(6): 494-501.
[155] McEleny KR,Watson RW, Coffey RN,et al. Inhibitors of apoptosis proteins in prostate cancer cell lines[J]. Prostate, 2002, 51:133-140.
[156]邵月婷,张灵,汲坤等. GRIM-19基因的克隆及其对小鼠前列腺癌细胞株的促凋亡作用.《基础医学与临床》2008,28 (1):13-17.
[157] Zhang M, Ho A, Hammond EH, Suzuki Y, et al. Prognostic Value of Survivin in Locally Advanced Prostate Cancer: Study Based on RTOG 8610. Int J Radiat Oncol Biol Phys. 2008,30. [Epub ahead of print] .
[158] Kucukzeybek Y, Gul MK, Cengiz E, et al. Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of Survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. J Exp Clin Cancer Res. 2008, 27(1):37-47.
[159] Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998, 391:806-811.
[160] Bernstein E, Caudy AA, Hammond SM, et al . Role for a bidentate ribonuclease in the initiation step of RNA interference [J]. Nature 2001, 409(6818): 363-366.
[161] Elbashir SM, Harborth J, Tuschl T, et al . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J]. Nature, 2001, 411 (6836): 494-498.
[162] Lewis D , Hagstrom J E, Loomis AG, et al. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice [J]. Nat Genet, 2002, 32 (1): 107-108.
[163] Fuessel S, Herrmann J, Ning S, et al. Chemosensitization of bladder cancer cells by Survivin-directed antisense oligodeoxynucleotides and siRNA [J]. Cancer Lett. 2006, 232:243-254.
[164]金冬雁译.克隆化基因在哺乳动物培养细胞中的表达[A].见J.萨姆布鲁克主编.分子克隆实验指南[M].第二版.北京:科学出版社. 1992,775-776.
[165] Li F,Ling X. Survivin Study: An Update of“What is the next wave?”[J]. J Cell Physiol, 2006, 208(1):476-486.
[166]Sudhakar Kalakonda, Shreeram C. Nallar, Ping Gong, et al. Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19inhibits src-induced oncogenic transformation at multiple levels The American Journal of Pathology, 2007,171(4): 1352-1368.
[167] Ma X, Kalakonda S, Srinivasula S M, et al. GR IM-19 associates with the serine protease HtrA for promoting cell death[ J ]Oncogene, 2007, 26 (33) :4842-4849.
[168]Alchanati I, Nallar SC, Sun P, et al. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Adv Anat Pathol. 2008, 15(1):46-53.
[169]Cheng chen Lufei, Jing Ma, et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. The EMBO Journal. 2003,22( 6 )1325-1335.
[170]Chen CL, Cen L, Kohout J,et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008, 21(7)78-86.
[171]Chelur DS, Chalfie M. Targeted cell killing by reconstituted caspase3. Pro Natl Acad Sci USA. 2007, 104(7):2283-2288.
[172] Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol, 2002, 3(9): 651-662.
[173] Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res, 2000, 60(14): 3689-3695.
[174] Jain N, Zhang T, Fong SL, et al. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene, 1998, 17(24): 3157-3167
[175] Nagy B, Szendroi A, Romics I. Overexpression of CD24, c-myc and Phospholipase 2A in Prostate Cancer Tissue Samples Obtained by Needle Biopsy.. Pathol Oncol Res. 2008 Aug 28. [Epub ahead of print] .
[176] Lee JG, Zheng R, McCafferty-Cepero JM,et al. Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Mol Carcinog. 2009, 48(2):141-149.
[177] Chen N, Chen X, Huang R, et al. BcL-xL is a target gene regulated by hypoxia-inducible factor-1-alpha. J Biol Chem. 2009 Feb 10. [Epub ahead of print].
[178] Li X, Marani M, Mannucci R, et al. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res 2001, 61: 1699-1706.
[179]Wang X, Zhang J, Kim HP, et al. BcL-xL disrupts death-inducing signal complex formation in plasma membrane induced by hypoxia/reoxygenation. FASEB J 2004, 18:1826-1833.
[180] Gabriel B, Sureau F, Casselyn M, et al. Retroactive pathway involving mitochondria in electroloaded cytochrome c-induced apoptosis. Protective properties of Bcl-2 and BcL-xL. Exp Cell Res 2003, 289: 195-210.
[181]Breckenridge DG, Xue D. Regulation of mitochondrial membrane permeabilization byBCL-2 family proteins and caspases. Curr Opin Cell Biol 2004, 16: 647-652.
[182] Bubendorf L, Sauter G, Moch H, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol, 1996, 178(4): 437-441.
[1] Schroder F, Walsh PC, Retik AB, et al. Hormonal therapy of prostate cancer.[M] Campbellps Urology. 8th ed. Philadelphia: W. B. Saunders Company, 2002, 3182-3208.
[2] Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. [J]. Urology, 2000, 56(6): 1021-1024.
[3] Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. [J].Cancer Res, 2002, 67 (2 Pt 2):948-951.
[4]鲍镇美.晚期前列腺癌的治疗新动向[J].中华泌尿外科杂志,2000,23(2): 69-72.
[5]应俊,姚德鸿,任晓敏.前列腺癌去势术前后雄性激素变化的研究[J].中华男科学,2003,6 (3):191～196.
[6]夏同礼.前列腺癌的基础与临床[M].北京:科学出版社,2000.227～238.
[7] Jiang W, Jiang C, Pei H, In vivo molecular mediators of cancer growth suppression and apoptosis by selenium in mammary and prostate models: lack of involvement of gadd genes. Mol Cancer Ther. 2009 Mar 10. [Epub ahead of print].
[8] Connell JM, Kir- by R, Connell J M, et al. 5 Alpha2 reductase in prostate disease[A]. Textbook of prostatic hyperplasia [M]. London: ISIS Medical Media. 1996, 85～90.
[9] Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects[J]. J Urol. 2001, 166(2):500～506.
[10]Oh WK. The evolving role of estrogen therapy in prostate cancer[J]. Clin Prostate Cancer, 2002, 1(2):81-89.
[11]Hedlund PO, Ala-opas M, Brekkan E , et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer- scandinavian prostatic cancer group(SPCG) study No. 5 [J]. Scand J Urol Nephrol, 2002, 36(6):405-143.
[12]Klotz L, McNeill I, Fleshner N. A phase 1 - 2 trial of diethylstilbestrol plus lowdose warfarin in advanced prostate carcinoma [J].J Urol. 1999, 161(1): 169-172.
[13]Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer [J]. Eur Urol, 2006, 49(1): 54-58.
[14]Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leup rolide plus daily antiandrogen in men with prostate cancer [J]. J Urol, 2002, 167(4):1670- 1674.
[15] Moffat LE. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer [J]. Eur Urol, 1990, 18 (3):26-27.
[161]Schroder FH, Whelan P, DeReijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the“European organization for research and treatment of cancer”(EORTC) protocol 30892 [J]. Eur Urol, 2004, 45(4):457-464.
[17]Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity [J]. J Urol, 1996, 155(1): 209-212.
[18]Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up[J]. J Urol, 2000, 164(5): 1579-1582.
[19]Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma[J]. Cancer, 2002, 5(2):361-376.
[20]Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review [J]. Urology, 2001, 7(4):727-732.
[21] Blackard CE, Byar DP, Jordan WP. Orchiectomy for advanced prostatic carcinoma. A reevaluation [J].Urology,1973, 1(6):553-560.
[22]Byar D P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. [J]. Cancer, 1973, 32(5):1126-1130.
[23] Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. [J].BrJ Urol, 1997, 79(2):235-246.
[24]Messing EM, Manola J, SarosdyM, et al. Immediate hormonal therapy comparedwith observation after radical prostatectomy in men with node positive prostate cancer [J]. N Engl J Med, 1999, 341(24): 1781-1788.
[25] Schulman CC, Debruyne FM, Forster G, et al. 42Year follow– up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2 - 3N0M0 prostate cancer. European study group on neoadjuvant treatment of prostate cancer [J]. Eur Urol, 2000, 38(6):706-713.
[26] Reese D M. Choice of hormonal therapy for prostate cancer [J]. Cancer, 2000, 355(9214):1473-1475.
[27] Shenk JL, Fisher CJ, Chen SY, et al. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 2001; 276(42): 38472-38479.
[28] Fujimoto N, Yeh S, Kang HY, et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate J Biol Chem 1999, 272(12): 8316-8321.
[29] Linja MJ, Savinainen KJ , Saramaki OR , et al.Amplification and overexpression of androgen receptor gene inhormone refractory prostate cancer. Cancer Res, 2001, 61 (9) : 3550-555.
[30] Taplin ME , Balk SP. Androgen receptor : A key moleculein the progression of prostate cancer to hormone independence. J Cell Biochem, 2004 , 91 (3) : 483-490.
[31] Lin MF, Meng TC, Rao PS, et al. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998; 273(10), 5939-5947.
[32] Culig Z, Hobisch A, Hittmair A. et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma Prostate 1998,35 (1): 63-70
[33]Brown RS, Edwards J, Dogan A, et al. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer J Pathol 2002, 198(2): 237-244.
[34] Koivisto P. Aneuploidy a nd rapid cell p rolif eration in recurrent prostate cancers with androgen receptor gene amplification [J], Prostate Cancer Prostatic Dis, 1997, 1(3):21-25.
[35] Edwards J, Krishna NS, Grigor KM, et al. Androgen receptor gene amplification and protein expression in hormone refrectory prostate cancer [J]. Br J Cancer,2003, 89(3):552-556.
[36]Chmelar R, Buchanan G, Need EF, et al . Androgen receptor coregulators and their involvement in the development and progression of prostate cancer [J]. Int J Cancer, 2007, 120 :719-733.
[37] Gregory CW, He B, Raymond T, et al. A mechanism for androgen receptor mediated prostate cancer recurrence after androgen deprivation therapy [J]. Cancer Res, 2000, 161(11): 4315-4319.
[38]Shen MM, Abate Shen C. Pten inactivation and the emergence of androgen independent prostate cancer [J]. Cancer Res, 2007, 67(14):6535-6538.
[39]Liao G, Chen LY, Zhang A, et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMR T [J].J Biol Chem,2003,278(7):5052-5061.
[40]Shenk JL, Fisher CJ, Chen S Y, et al. p53 represses androgen induced transactivation of prostate specific antigen by disrupting hAR amino to carboxylterminal interaction [J]. J Biol Chem, 2001, 276(42):38472-38479.
[41] Gurova KV, Roklin OW, Krivokrysenko V, et al. Expression of prostate specific antigen is negatively regulated by p53[J]. Oncogene, 2002, 21(1):153-157.
[42]Burchardt M, Burchardt T, Shabsigh A, et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells [J]. Prostate, 2001, 48(4):225-230.
[43] Corcoran NM, Costello AJ . Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer BJU Int, 2003, 91 (6): 545-553.
[44] Gioeli D , Ficarro SB , Kwiek JJ , et al . Androgen receptorphosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem, 2002, 277 (32 ) :29304-29314.
[45]Murtha PE, Zhu W, Zhang J , et al . Effects of Ca2 + mobilization on expression of androgen regulated gene: interference with androgen receptor mediated transactivation by AP21 proteins. Prostate, 1997 , 33 : 264-270.
[46] Cronauer MV, Schulz WA , Burchardt T , et al . The androgen receptor in hormone refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol, 2003, 23 (4): 1095-10102.
[47] Murillo H , Schmidt LJ , Tindall DJ , et al . Tyrphostin AG825 triggers p38 mitogen-activated protein kinase dependent apoptosis in androgen independentprostate cancercells C4 and C422. Cancer Res, 2001, 61 (20) : 7408-74012.
[48] Heinrich PC, Behrmann I , Haan S , et al. Principles ofinterleukin ( IL) -6 type cytokine signalling and its regulation. Biochem J, 2003, 374 (Pt 1): 1-20.
[49] Sadar MD, Gleave ME. Ligand independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res, 2000, 60(20) : 5825-5831.
[50]Ye J , Wang S , Barger M , et al . Activation of androgen response element by cadmium: a potential mechanism for acarcinogenic effect of cadmium in the prostate. J Environ Pathol Toxicol Oncol, 2000 , 19 (3) : 275-280.
[51] Yeh S, Sampson ER , Lee DK, et al . Functional analysis of androgen receptor N terminal and ligand binding domain interacting coregulators in prostate cancer. J Formos MedAssoc , 2000, 99 (12) : 885-894.
[52]Ueda T , Mawji NR , Bruchovsky N , et al . Ligand independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostatecancer cells. J Biol Chem, 2002 , 277 ( 41) : 38087-38094.
[53] Lee DK, Duan HO, Chang C , et al . From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH (2) 2terminal associated coactivator. J Biol Chem , 2000 , 275 (13) : 9308-9313.
[54] Wang X , Deng H , Basu I , et al . Induction of androgen receptor dependent apoptosis in prostate cancer cells by the retinoblastoma protein. Cancer Res, 2004 , 64 ( 4) : 1377-1385.
[55] Sharma M, Sun Z. 5′TG3′interacting factor interacts with sin3A and represses AR mediated transcription. MolEndocrinol 2001, 15 (11) : 1918-1928.
[56] Comuzzi B, Lambrinidis L , Rogatsch H. The transcriptional coactivator cAMP response element2binding protein2binding protein is expressed in prostate cancer and enhances androgen2 and anti2androgen2induced androgen receptor function. Am J Pathol, 2003, 162 (1) : 233-241.
[57] Chen CD , Welsbie DS , Tran C , et al . Molecular determinants of resis2tance to antiandrogen therapy [J]. Nat Med, 2004, 10(1) :33.
[58] Gregory CW, Johnson RT , Mohler JL , et al . Androgen receptor stabiliza2tion in recurrent prostate cancer is associated with hypersensitivity to low androgen [J ] . Cancer Res, 2001,61 (7):2892.
[59]Weber MJ, Gioeli D. Ras signaling in prostate cancer progression [J ] . JCell Biochem, 2004,91 (1) :13-24.
[60] Matias PM, Donnor P , Coelho R , et al . Structure evidence for ligand specificity in the binding domain of the human androgen receptor: implications for pathogenicgene mutations. J Biol Chem, 2000 , 275(34): 26164-26171.
[61]Corcoran NM, Costello AJ . Interleukin26: minor player or starring role in the development of hormone2refractory prostate cancer ?BJU Int , 2003 , 91 (6) : 545-553.
[62]Mononen N , Syrjakoski K, Matikainen M , et al . Two percent of Finnish prostate cancer patients have a germline mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res, 2000, 60 (22): 6479-6481.
[63] Gottlieb B, Beitel LK, Lumbroso R, et al. Update of the androgen receptor gene mutations database. Hum Mutat,1999, 14(2): 103-114.
[64]Peterziel H, Culig Z, Stober J, et al. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding Inst J Cancer 1995, 63(4): 544-550.
[65]Ceraline J, Erdmann E, Erbs P, et al. A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer Eur J Endocrino, 2003, 148(1): 99-110.
[66]Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res 1999,59(11): 2511-2515.
[67] Elo JP, Kvist L, Leinonen K, et al. J Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol Clin EndocrinolMetab 1995, 80(12): 3494-3500.
[68]Wang LG, Ossowski L, Ferrari AC. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line Cancer Res 2001, 61(20): 7544-7551.
[69]Nazareth LV, Stnioen DL, Bingman WE, et al. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) Mol Endocrinol1999, 13(12): 2065-2075.
[70] Marcelli M, Ittmann M, Stefania M, et al. Androgen receptor mutations in prostate cancer Cancer Res2000, 60(4): 944-949.
[71]ZhaoXY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 2000, 6(6): 703-706.
[73]Grande M,Carlstrom K,Rozell BL,et al.Tissue concentrations of tissuepolypeptide antigen(TPA) and prostatic specific antigen(PSA) in 42 pa2tients with prostatic carcinoma[J ] . Prostate ,2000 ,45 (4) :299.
[73] Cluetjens CBJM, Steketee K, van Eekelen CCEM, at al . Both androgenreceptor and gllucocorticoid receptor are able to induce prostate - specif2ic antigen expreesion ,but differ in their growth stimulating properties ofLNCaP cell [J ] . Endocrinology ,1997 ,138 (12) :5293.
[74]Devon A, Lawson, Owen N. Witte, et al. Stem cell in prostate cancerinitiation and progression[J ] .Clin. Invest, 2007 ,117(18) :2044.
[75]Collins AT, Berry PA, Hyde C, et al . Prospective identification of tumorigenic prostate cancer stem cells [J ] . Cancer Res , 2005 , 65 (23) :10946-10951.
[76]O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17- hydroxylase/ C (17, 20) - lyase inhibitor abiraterone acetate(CB7630) in patients with prostate cancer [J ] . Br J Cancer ,2004 ,90(12) :2317-2325.
[77]Adam Schayowitz, Gauri Sabnis, Vincent C. O. Njar, et al . Synergisticeffect of a novel antiandrogen, VN/ 124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro[J] . Molecular Cancer Therapeutics, 2008 ,7 (1) :121-132.
[78] Stec A, Mochol J, Kurek L , et al. The influence of different factors on selenium levels in dairy cow herds in the central– eastern region of Poland. Polish Journal of Veterinary Science, 2005,8(3):225-229.
[79]Luoma P. Antioxidants, infections and environmental factors in health and disease in northern Finland. International Journal of cir cumpolar Health, 1998;57(2～3):109-113.
[80]张在香.哺乳动物硒蛋白的研究进展.生理科学进展.1998,29(1):29-31.
[81]Wu QZ, Kuang KX. Effect of long-term Se deficiency on the antioxidant capacities of rat vascular tissue. Biological Trace Element Research, 2004, 98(2):73～84.
[82]赵晶,康世良,王伟.肌注亚硒酸钠后仔猪血硒浓度与抗氧化系统动态变化.动物医学进展,2002,23(6):93～100
[83]Smith A, Madden KB, Yeung KJ, et al. Deficiencies in selenium and/or vitamin E the resistance of mice to Helig–mosomoides polygyrus infections, Journal of Nutrition, 2005, 135(4):830～836.
[84] Albers R, Bol M, Bleumink R et al. Effectes of supplementation with vitamins A, C,and E, selenium, and zinc on immune function in a murine sensitization model. Nutrition, 2003, 19 (11-12):940～946.
[85] Ogunlewe J. Zinc and cadmium concentration - digenous biacks with normal, hypertrophy,and malignant prostate. Cancer, 1989, 63(3) :1388-1391.
[86]高楠,陈维佳.微量元素硒与人类健康最新研究进展.沈阳医学院学报, 2003,5(4):259～264.
[87] Nouarie M, .Pourshams A, Kamangar F, et al. Ecologic study of serum selenium and upper gastrointestinal cancers in Iran [J]. World J Gastroenterology,2004, 10(17): 2544-2546.
[88]Jacobs E T, Jiang R, Alberts D S, et al. Selenium and colorectal adenoma: results of a pooled analysis[J]. J Natl Cancer Inst, 2004, 96(22):1669-1675.
[89] Wei W Q, Abnet C C, Qiao Y L, et al. Prospective study of serum selenium concentrations and esophageal and gastric cardiac cancer, heart disease, stroke, and total death[J]. Am J Clin Nutr, 2004, 79(1):80-85.
[90] Kellen E, Zeegers M, Buntinx F.Selenium is inversely associated with bladder cancer risk:a report from the Belgian case control study on bladder cancer[J].Int J Urol,2006, 13(9):11802-11804.
[91] Thirunavukkarasu C, Babu E, Ebrahim A S, et al. Antioxidant associated chemoprevention by sodium selenite in nitrosodiet hylamine2induced and Phenobarbital promoted hepatocarcinogenesis in rats[J].Cell Biochem Funct, 2004, 22(4):265-271.
[92]刘家国,赵洪进,王小龙,等.富硒麦芽对二乙基亚硝胺所致大鼠肝癌、伴癌综合征及血糖调节相关激素的影响[J].南京农业大学学报,2005,28(4): 90-95.
[93] Liu JG, Zhao HJ, Wang XL, et al. Effect of selenium enriched malt on hepatocarcinogenesis, paraneoplastic syndrome and the hormones regulating blood glucose in rats treated by diet hylnitrosamine, 2006, 78(20):2315-2321.
[94]刘泽,崔文明,韩驰.富硒茶防癌作用实验研究[J].中国职业医学, 2005, 32 (4):22-24.
[95]Rudolf E, Radocha J, Cervinka M, et al. combined effect of sodium selenite and campthotecin on cervical carcinoma cells. Neoplasma,2004, 51(2):127-135.
[96]王敏,朱劲华,马宇翔.含硒紫球藻胞外多糖的制备及对体内外肿瘤细胞生长的影响[J].海洋科学,2006, 30(1):23-27.
[97]Zhao H, Whitfield M L, Xu T, et al. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells[J] . Mol Biol Cell,2004, 15(2): 506-519.
[98]刘艳波,赵丽娟,赵雪俭等.甲基化硒酸对人前列腺癌DU145细胞增殖与凋亡的影响.吉林大学学报(医学版),2008, 34(6):967-910.
[99]轩艳,张宝元,周玲.硒元素对卵巢癌患者化疗的影响[J].国外医学:医学地理分册,2005, 26(2):58-61.
[100] Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients[J].Cochrane Database Syst Rev,2006, 3 19;3:CD005037.
[101] YenJK, ChaSD, ChoCH, et al. Se methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpainin SKOV23 ovarian cancer cells[J].Cancer Lett,2002,182(1):83-92.
[102]Medina D, Thompson H, Ganther H, et al. Se methylselenocysteine:a new compound for chemoprevention of breast cancer[J].Nutr Cancer,2001, 40 (1):12-17.
[103]Jiang C, Wang Z, Ganther H, et al. Caspases as key executors of Methylselenum induced apoptosis(anoikis)ofDU145 prostate cancer cells[J].Cancer Res,2001, 61(7):3062-3070.
[104]Jung U, Zheng X, Yoon SO, et al. Se methylselenocysteine induces apoptosis mediated by reactive oxygen species in HL260 cells[J]. Free Radic Biol Med, 2001, 31(4):479-483.
[105]Ip C, Thompson HJ, Zhu Z, et al. In vitro and in vivo studies of Methylseleninic acid: evidence that amonomethylatedselenium metabolite is critical for cancer chemoprevention [J].Cancer Res, 2000, 60(11):2882-2886.
[106]Dong Y, Soo OL, Zhang HT, et al. Prostate specific antigen expression Is downregulated by selenium through disruption of androgen receptor signaling [J].Cancer Res,2004,64(1):19-22.
[107]Soo OL, Nadiminty N, Xiu XW, et al. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells[J].Cancer Res,2005,65 (8) :3487-3492.
[108]SinhaR, Unni E, Ganther HE, etal. Methylseleninic acid, a potent growth inhibitor of synchronized mouse mammary epithelial tumor cells in vitro [J]. Bio chem. Pharmacol, 2001, 61(3):311-317.
[109] DongY, Zhang H, Hawthorn L, et al. Delineation of the molecular basis for selenium induced growth arrest in human prostate cancer cells by oligonucleotide array [J].Cancer Res,2003,63 (1) :52-59.
[110] Lu Zuo, Jian Li, Yang Yang, et al. Sodium selenite induces apoptosis in acute promyelocytic leukemia derived NB cells by a caspase 3dependent mechanism and a redox pathway different from that of arsenic trioxide [J].Ann Hematol,2004, 83(12):751 -758.
[111] Zhao R, Xiang N, Frederick E, et al. Expression of p53 enhances selenite induced superoxide production and apoptosis in human prostate cancer cells[J]. Cancer Res, 2006, 66 (4):2296-2304.
[112]Zeng H, Mary B A, Joseph PI, et al. The selenium metabolite methylselenol inhibits the migration and invasion potential of ht1080 tumor cells [J]. JNutr, 2006, 136(6):1528 -1532.
[113] Zhu Z, Kimura M, Itokawal Y, et al. Effect of selenium on malignant tumor cells of brain[J]. Biol Trace Elem Res.1995, 49(1):1-7.
[114] Danesi F, Malagut IM, Nunzio M D, et al. Counteraction of adriamycin-lnduced oxidative damage in rat heart by selenium dietary supplementation[J].Agric Food Chem 2006, 54(4): 1203-1208.
[115] Fang Y Z, Yang S, Wu G Y. Free radicals, antioxidants,and nutrition[J]. Nutrition,2002,18(10):872–879.
[116] Al-taie O H, Uceyler N, Eubner U, et al. Expression profiling and genetic alterations of the selenoproteins GI-GPx and Se PP in colorectal carcinogenesis [J]. Nutr Cancer,2004, 48(1):6-14.
[117]Yang JY, Wang ZR. The antitumor effects of selenium compound Na5SeV5O18.3H20 in K562 cell [J].Arch Pharm Res,2006,29(10):859-865.
[118]Wu Y, Zhang H, DongY, et al. Endoplasmic reticulum stress signal mediators are targets of selenium action [J].Cancer Res,2005,65(10) :9073-9079.
[119] KimYS, Jhon DY, Lee KY. Involvement of ROS and JNK 1ink selenite induced apoptosis in Chang liver cells[J]. Exp Mol Med 2004,36(2):157-164.
[120] Jun P, Liu W. The responses of HT22 cells to the blockade of mitochondrial complexes and potential protective effect of selenium supplementation [J]. Int J Biol Sci,2007,3 (5) :335-341.
[121]孙茹,王欣,魏欣冰,等.羟乙葛根素对大鼠局灶性脑缺血再灌注损伤细胞凋亡及p53表达的影响[J].中国生化药物杂志,2004,25 (6):336-338.
[122]Hu H, Jiang C, Schuster T, et al. Inorganic selenium sensitizes prostate cancer cells to TRAIL induced apoptosis through superoxide/p53/Bax mediated activation of mitochondrial pathway [J]. Mol Cancer Ther, 2006,5(7):1873-1882.
[123]裴小娟,苏敏,田东萍.硒-甲基硒代半胱氨酸对人食管癌EC109细胞Ki-67及Bcl-2/Bax蛋白表达的影响[J].汕头大学医学院学报,2004,17(2):65- 67.
[124]张哲文,魏虎来,苏海翔,等.硒酸酯多糖诱导白血病多药耐药细胞凋亡的作用机制[J].中国临床药理学与治疗学,2005;10(5):505-508.
[125]张敬,张军,赵燕,等.硒化合物和维生素E对白血病细胞凋亡及c-Myc基因表达的影响[J].营养学报,2001,23(4):324-326.
[126]Alexander V, Gasparian, YaoY, et al. Selenium compounds inhibit IκB kinase (IKK) and nuclear factorκB (NF-κB) in prostate cancer cells [J]. Mol Cancer Ther, 2002, 10 (1):1079-1087.
[127]DongY,Ganther HE, Stewart C, etal. Identification of molecular targets associated with selenium induced growth inhibition in human breast cancer cells using cDNA microarrays [J].Cancer Res, 2002,62(3):708-714
[128] Zhu Z, Jiang W, Ganther HE, et al. Mechanisms of cell cycle arrest by methylseleninic acid [J].Cancer Res,2002,62(3):152-164.
[129]El, Bayoumy K, Sinha R. Molecular chemoprevention by selenium : age nmic approach [J].Mutat Res Fundam Mol Mech Mutagen,2005, 591(122) :224-236.
[130]Zhao H, Michael L, Whitfield, et al. Diverse effects of methylse Leninic acid on the transcriptional program of human prostate cancer cells [J].Mol Biol Cell, 2004, 2 (15) :5022519.
[131]冯月秋,王束枚,张岫美.乙酰葛根素对血管紧张素Ⅱ致血管内皮细胞凋亡的抑制作用[J].中国生化药物杂志,2007;28(1):11-14.
[132]赵任,郁宝铭,郑民华,等.硒化合物对淋巴细胞杀伤大肠癌细胞过程中Fas/FasL表达的影响[J].中华实验外科杂志,2001;18(1):21-23.
[133]Kim I Y, Stadtman T C. Inhibition of nf-kb dna binding and nitric oxide induction in human t cells and lung adenocarcinoma cells by selenite treatment[J].Proc Natl Acad Sci USA, 199, 94(24): 12904-12907.
[134]Howard E G.Selenium metabolism selenoproteins and mechanisms of cancer prevention complexities with thioredoxin reductase [J].Carcinogenesis, 1999, 20(9):1657-1666.
[135]Kiremidjian-Schumacher L, Roy M.Selenium and immune function [J]. Ernahrungswiss,1998, 37(Suppl1):50-56.
[136]Shi C Y, Chua S C, Lee H P, et al. inhibition of afiatoxinbl-DNA binding and adduct formation by selenium in rats[J].Cancer Lett, 1994, 82(2):203-208.
[137]Erin E B, Nathan R P, Julia L B. The Central Role of Metal Coordination in Selenium Antioxidant Activity[J]. Inorg Chem, 2006, (45): 499-501.
[138]Wilke B C, Viddailhet M, Favier A, et al. Selenium glutathione peroxidsase (GSH-Px) and lipid peroxidation products before and after selenium supplementation[J].Clin Chim Acta, 1992, 207(1-2):137-142. .
[139] Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumor genesis [J]. Cel, 1996, 86 (3): 353-364.
[140] Zetter BR. Angiogenesis and tumor metastasis [J]. Annu Rev Med, 1998, 49(4) : 407-424.
[141]Grunstein J, Roberts WG, Mathieu Costello O, et al. Tumor derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function [J]. Cancer Res,1999, 59 (7) :1592-1598.
[142]Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promote ractivity in stromal cells [J]. Cel , 1998, 94(6): 715-725.
[143] Ferrara N, Carver-Moore K, Chen H, et al. Heterozgous embryonic lethality induced by targeted inactivation of the VEGF gene[J]. Nature, 1996, 380(4): 439-442.
[144] Aonuma M, Saeki Y, Akimoto T, et al . Vascular endothelial growth factor overproduced by tumor cells acts predominantly as a potent angiogenic factor contributing to malignant progression[J]. Int J Exp Pathol, 1999, 80(5): 271-281.
[145] Deroanne CF, Hajitou A, Calberg-Bacq CM, et al. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up regulation of vascular endothelial growth factor expression[J] . Cancer Res, 1997,7(24): 5590-5597.
[146]Eric A, Ian M, Scott M, et al. The selenium and vitamin E cancer prevention trial [J ].Urologic Oncology,2003, 21(2):59-65.
[147] Karam EB, Arunang SD, Telih B, et al. Comparative action of 1 ,4phenyleneb is (methylene) selenocyanate and it s metabolites against 7 , 1-2dimet hylbenz [ a ] anthracene-DNA adduct formation in the rat and cell proliferation in rat mammary tumor cells [J]. Chemico Biological Interactions,2003, 146 (2): 179-190.
[148]Jiang C, Ganther H, Lu JX. Monomethyl selenium specific inhibition of MMP2 and VEGF expression:implications for angiogenic switch regulation [J]. Mol Carcinog, 2000, 29 (4):236-250.
[149]Clark LC, Combs GF, Turnbull BW, et al. Effect s of selenium supplementation for cancer prevention in patient s with carcinoma of the skin: a randomized controlled trial [J]. JA-MA, 1996, 276(24):1957-1963.
[150]Guidi A J, Schnitt SJ, Fischer L, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patient s with ductal carcinoma in situ of the breast [J]. Cancer, 1997, 80(10) :1945-1953.
[151]Folkman J. The role of angiogenesis in tumor growth[J]. Semin Cancer Biol,1992, 3(2): 65-71.
[152]Wang Z, Jiang C, Ganther H, et al. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3 KA KT, ERK, JNK and p38MARK signaling [J]. Cancer Res, 2001, 61(19): 7171-7178.
[153] Stewart MS, Spallholz JE, Neldner KH, et al. Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis[J]. Free Radic Bio Med, 1999, 26(1-2): 42-48.
[154]王坤,迟永春,王君,等.微量元素硒对HL-60细胞凋亡的诱导及bcl-2/bax基因的表达调控[J].中日友好医院学报,2001;15(3): 150-155.
[155]张敬,张军,赵燕,等.硒和维生E对白血病细胞凋亡及c-Myc基因表达的影响[J].营养学报,2001;23(4):324-326
[156]Caffrey PB, Frenkel GD. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo[J].Cancer Chemother Pharmacol,2000 ,(46): 74-78.
[157]俸家富.硒蛋白和硒的抗癌机理[J].微量元素与健康研究,2001;18(1): 70 -72.
[158]Cindy D, Eric OV, John WF. Dietary selenium and arsenic affect DNA ethylation in vitro in CACO cells and in vivo rat liver and colon[J]. ASNS, 2000, 130(12): 2903-2909.
[159]Zhang GX, Zhao ZQ, Wang HD. Enhancement of osteopontin expression in HepG-2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway [J].World J Gastroenterol, 2004, (10): 205-208.
[160] Klein EA. Selenium-epidemiology and basic science [J]. J Urol, 2004, 171(2pt2):50-53.
[161]Ashughyan VR, Marihart S, Djavan B. Chemopreventive Trials in Urologic Cancer [J]. Reviews in urology 2006, 8(1):8-13.
[162] Brinkman M, Reulen RC, Kellen E,et al. Are men with low selenium levels at increased risk of prostate cancer [J] Eur J Cancer, 2006, 42(15), 2463–2471.
[163]Vogt TM, Ziegler RG, Graubard BI, et al. Serum Se and risk of prostate cancer in U.S. blacks and whites [J].Int J Cancer, 2003,103(5):664-670.
[164]Dufield-Lillico AJ, Dalkin BI, Reid ME, et al. Se supplementation, baseline plasma Se status, and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer study group[J]. Br J Urol Int, 2003,91(7):608-612.
[165]Van den Brandt PA, Zeegers MP, Bode P, et al. Toenail selenium levels and the subsequent risk of prostate cancer:a prospective cohort study[J] .Cancer Epidemiol Biomarkers Prev ,2003,12(9):866-871.
[166] Zhao H , Whitfield ML, Xu T, et al. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells[J]. Mol Biol Cell, 2004,15(2):506- 519.
[167]Cho SD, Jiang C, Malewicz B, et al. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription[J]. Mol Cancer Ther , 2004, 3(5): 605–611.
[168]Lee SO, Chun JY, Nadiminty N, et al. Monomethylated Selenium InhibitsGrowth of LNCaP Human Prostate Cancer Xenograft Accompanied by a Decrease in the Expression of Androgen Receptor and Prostate-Specific Antigen(PSA)[J]. Prostate,2006,66(4):1070- 1075.
[169]Waters DJ, Shen S, Cooley DM,et al. Effects of dietary Se supplementation on DNA damage and apoptosis in canine prostate[J]. J Natl Cancer Inst,2003,95(3):237-241.
[170]Gianduzzo TR, Holmes EG, Tinggi U, et al. Prostatic and peripheral blood selenium levels after oral supplementation [J]. J Urol,2003, 170(3): 870-873.
[171]Bhamre S, Whitin JC, Cohen HJ. Selenomethionine does not affect PSA secretion independent of its effect on LNCaP growth [J]. Prostate, 2003,54(4): 315-321.
[172]Rebsch CM, Penna FJ, Copeland PR. Selenoprotein expression is regulated at multiple levels in prostate cells [J]. Cell Res. 2006, 16(12): 940-948.
[173] Pinto JT, Sinha R, Papp K, et al. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells[J]. IntJ Cancer. 2007, 24(7):1410-1417.
[174] Zu K, Ip C. Synergy between selenium and Vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells[J]. Cancer Res, 2003,63(20): 6988-6995.
[175]应俊,姚德鸿,任晓敏.前列腺癌去势术前后雄性激素变化的研究[J].中华男科学, 2003,6(3):191～196.
[176]夏同礼.前列腺癌的基础与临床[M].北京:科学出版社,2000,227～238.
[177] InWalsh PC , Retik A B , Vaughan E D, of the prostate and seminal vesicles [A].et al.Campbell’s Urology[M]. 7thed, New York: Philadephia , Saunder, 1998, 1379～1428.
[178]Connell JM. 5-Alpha reductase in prostate disease[A].Kirby R, Connell J M, Fitzpatrick J,et al. Textbook of prostatic hyperplasia[M].London: ISIS Medical Media,1996, 85～90.
[179]Arner ES, Holmgren A. The thioredoxin system in cancer [J]. Semin. Cancer Biol, 2006, 16(6):420-426.
[180]Grubb RL 3rd, Black A, Izmirlian G,Serum Prostate-Specific AntigenHemodilution Among Obese Men Undergoing Screening in the Prostate, Lung, Colorectal, and Ovarian [181]Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009, 18(3):748-751.
[181]Dudkin VY, Miller JS, Dudkina ASToward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. J Am Chem Soc. 2008, 130(41):13598-13607.
[182] Jiang H, Semenza GL, Bauer C, et al. Hypoxia-inducible factor-1 level vary exponentially over a physiologically relevant range of O2 tense[J]. Am J Physiol, 1996, 271(4 pt1):1172-1180.
[183]Semenza GL. Regulation of mammalian O2 hemeostasis by hypoxia-inducible factor 1 [J]. Annu Rev Cell Dev Biol, 1999,15(8): 551-578.
[184] Carmeliet P, Dor Y, herbert JM,et al. Role of HIF-1 alpha in hypoxia-mediated apopotosis cell prolifewration and tumor angiogenesis[J]. Nature,1998, 394(6692) :485-499.
[185] Zhong H, Demarzo AM, Laughner E,et al. Overexpression of hypoxia-inducible factor 1 alpha in comom human cancers and their metastases[J]. Cancer Res, 1999, 599(22): 5830-5835.
[186]Ling MT, Wang X, Lee DT, et al. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Carcinogenesis, 2004, 25(4): 517-525.
[187]Taplin ME, Ho SM. Clinical review 134: The endocrinology of prostate cancer. J Clin Endocrinol Metab, 2001, 86(8): 3467-3477.
[188]Twillie DA, Eisenberger MA, Carducci MA, et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 1995, 45(3): 542-549.
[189]Assikis VJ, Do KA, Wen S, Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res. 2004, 10(20):6770-8.
[190]Huang HF, Murphy TF, Shu P, Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer. 2005, 4(1):25-38.
[191]Dong Y, Zhang H, Hawthorne L, et al. Delineation of the molecular basis for Se-induced growth arrest in human prostate cancer cells by oligonucleotide array[J]. Cancer Res, 2003,63:52-59.
[192]Zhang H, Wu Y, Malewicz B, et al.Augmented suppression of androgen receptor signaling by a combination of alpha-tocopheryl succinate and methylseleninic acid, 2006, 7(12):2942-2948.
[193]Lee SO, Chun JY, Nadiminty N,et al. Monomethylated Selenium Inhibits Growth of LNCaP Human Prostate Cancer Xenograft Accompanied by a Decrease in the Expression of Androgen Receptor and Prostate-Specific Antigen(PSA)[J]. Prostate, 2006,66(4):1070- 1075.